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Abstract
Aims
The Sodium Iodide Transporter (NIS), which is located in the basolateral membrane of 
the thyroid follicular cell, catalyses an active transport mechanism allowing Iodide, an 
essential component of the thyroid hormones Tri-iodothyronine (T3) and Thyroxine (T4), 
to accumulate in the thyroid gland. Differentiated thyroid cancers retain the appearance and 
function of normal thyroid cells, and can, therefore, trap iodine. Radioiodide scintigraphy and 
therapy are based on the uptake of radioiodide by NIS in thyroid tissue, which can concentrate 
all isotopes of iodine. 
Breast cancer is the most common type of cancer in women in the UK, and is the second-
most common cause of cancer-related death in women in the UK. This situation remains true 
in Scotland, with breast cancer representing 27.5% of all female cancers. Despite a reduction 
in	mortality	figures	between	1994	and	2004	of	18%,	five-year	survival	in	Scotland	remains	
only 80.2% for patients diagnosed between 1997 and 2001. When breast cancer recurs and 
becomes metastatic, it is treatable but not curable. Median overall survival of patients with 
metastatic disease remains poor, and is currently between one and two years. It is clear that 
metastatic breast cancer remains a challenging clinical issue and novel treatments are required.
Radionuclides play an important role in the management of malignancy, including prostate 
cancer, neural crest tumours and thyroid cancers. There is evidence that there may be a role 
for	radionuclide	therapy	in	breast	cancer	via	the	NIS	mechanism.	This	was	first	suggested	by	
Tazebay’s	landmark	work	in	2000,	which	demonstrated	that	a	significant	proportion	(87%)	of	
breast cancers contained detectable NIS protein by immunohistochemistry (IHC).
Experimental design
Tumour samples from patients with breast cancer were analysed by immunohistochemistry 
and ribonucleic acid (RNA) analysis, and this was correlated with functional activity of the 
NIS protein, by scintigraphic scanning of patients with metastatic breast cancer.ix
Results
Twenty-four patients had a Tc99m Pertechnetate scan; 20 patients had their RNA analysed; 
22 patients had IHC performed on their tumour samples. NIS was detected only in the control 
Graves	thyroid	RNA	and	paraffin	embedded	cells	extracted	from	a	NIS	expressing	cell	line.	
Breast	tumour	sample	RNA	did	not	demonstrate	NIS.	By	IHC,	15	cases	were	defined	as	
truly immunopositive, with the criteria for true positivity being a Histoscore of > 150, or 
demonstration of membrane staining. Seven cases were negative by the above criteria.  Tc99m 
Pertechnetate uptake was observed in 11 of 24 patients who were scanned, i.e., 46%.
Of these 15 patients with positive expression of NIS in their breast cancer tissue sample, as 
measured by immunohistochemistry, 14 cases were also scanned. Of these, eight patients 
(57%) demonstrated uptake of Tc99m Pertechnetate on scintigraphy, i.e., were true positives; 
six did not, i.e., their screening test (IHC) had incorrectly predicted positive uptake on 
subsequent scanning (false positive screening). Therefore, a positive predictive value of 57% 
was observed when using IHC as a screening test for detecting those patients who would go 
on to have a positive scan. In contrast, six patients had negative NIS expression by IHC, and 
no uptake on scintigraphy, i.e., true negatives. Only one patient had a false negative screening 
IHC result. A negative predictive value of 86% was seen when using immunocytochemistry as 
a screening test for detecting those patients who would have a negative scan. Sensitivity was 
88%,	with	a	specificity	of	50%.
Conclusions
This data has shown that the prevalence of patients with metastatic breast cancer expressing 
NIS on IHC is relatively high (68%), when compared with one other published study of 
similar patients(79). Also, it has been demonstrated that a high proportion of NIS IHC positive 
patients who were scanned (57%) demonstrated uptake of Tc99m Pertechnetate in breast 
cancer primary or metastases.
It can be concluded that IHC does act as a useful screening test for those who may ultimately 
benefit	from	radioisotope	treatment.	The	most	appropriate	radioisotope	for	therapy	remains	to	
be determined.1
Chapter 1 – Introduction
Introduction
The thesis is that the known expression of the sodium iodide symporter (NIS) gene in 
human breast cancer tissue can be exploited as an imaging and therapeutic target. The 
ultimate purpose of this research is to develop novel radionuclide imaging and therapeutic 
strategies, in which radiohalides are administered to patients with breast carcinomas 
which	express	the	NIS	gene.	Specific	objectives	of	this	research	are:
  to quantify NIS RNA expression and NIS protein levels in archival specimens of  (a) 
breast carcinoma samples and axillary lymph node metastases.
  To evaluate [ (b)  99mTc]-pertechnetate (99mTcO4) scintigraphy in patients with advanced 
NIS-positive breast carcinoma as a method of imaging metastatic deposits. The 
intensity of 99mTcO4-generated images will be compared with the levels of NIS RNA 
and protein expression in the patients’ archived material. The  99mTcO4-generated 
images of metastatic deposits will be compared with standard imaging techniques.
In	 the	 introduction,	 the	 management	 of	 thyroid	 cancer	 and	 breast	 cancer	 is	 briefly	
reviewed, the role of targeted therapies and radionuclide therapies in cancer management 
is discussed and a strategy for exploiting NIS expression in the management of breast 
cancer is proposed. 
 2
Section 1 – Thyroid Cancer
Radioiodine has for many years been the mainstay of treatment in metastatic thyroid 
cancer.  The  wealth  of  experience  accumulated  in  the  radioisotope  treatment  of  this 
tumour type is of potential use in evaluating radioisotope treatment strategies that may 
be applicable to patients with other types of cancer. One example of this is in the case of 
metastatic breast cancer, by exploiting knowledge of the biological pathways which may 
be common to the two cancers such as the sodium iodide symporter.
1.1 – Incidence, Survival and Aetiology of Thyroid Cancer
Thyroid cancer represents roughly 1% of all cancers, but is the most common malig-
nant endocrine tumour. The peak age of incidence is in the third and fourth decade with 
females	being	more	commonly	affected	in	a	ratio	of	3:1.	The	Scottish	annual	incidence	
between 1997 and 2001 was reported to be 2.4 per 100,000 women and 0.9 per 100,000 
men(1).	Standardised	five-year	survival	rates	for	the	period	1997-2001	were	recorded	as	
being 76% for men and 71% for women, aged between 15 and 74(1).
The aetiology of thyroid cancer is poorly understood. Irradiation of the neck during 
childhood,  and  exposure  to  ionizing  radiation  from  nuclear  fallout,  as  seen  in  the 
Chernobyl incident, have both been associated with an increased incidence(2)(3). Genetic 
abnormalities  may  have  a  key  role  in  pathogenesis(4).  RET/PTC,  NTRK  and  BRAF 
mutations are commonly seen in papillary thyroid cancer, while Ras, PTEN mutations 
and PPAR [gamma]–PAX8 rearrangement are recognised gene mutations for follicular 
thyroid cancer(5)(6). 
1.2 – Pathophysiology of Normal and Malignant Thyroid
Iodide, which is an essential component of the thyroid hormones tri-iodothyronine (T3) 
and thyroxine (T4), accumulates in the thyroid gland via an active transport mechanism 
catalysed by the sodium iodide symporter, which is located in the basolateral membrane 
of	the	thyroid	follicular	cell	(see	figure	one).3
NIS-mediated  iodide  accumulation  is  under  the  control  of  pituitary-derived  thyroid-
stimulating	hormone	(TSH).	A	TSH	responsive	element	(TRE)	has	been	identified	in	the	
NIS	promoter	region,	which	is	under	cyclic-AMP	control	and	is	thyroid	specific(7).  It has 
been shown that TSH stimulates NIS transcription and biosynthesis but is also involved in 
post-transcriptional regulation of NIS function(8). This group also demonstrated that TSH 
was required for effective targeting of NIS to the plasma membrane.
Iodide is transported towards the colloid compartment of the thyroid cell by a process 
known	as	iodide	efflux.	This	is	generally	thought	to	be	mediated	by	a	protein	called	
pendrin(9).	Thereafter,	iodide	is	organified,	a	complex	process	involving	thyroid	peroxidase,	
resulting in incorporation of iodide into tyrosyl residues in the thyroglobulin molecule 
(see	figure	two).	Thus,	iodide	is	stored	in	colloid,	available	to	be	secreted	into	the	blood	
as thyroid hormones when required.
Papillary and follicular carcinomas account for up to 90% of all cases of thyroid cancer 
and are collectively referred to as differentiated thyroid cancer. The remainder comprises 
anaplastic and medullary carcinoma, lymphomas and, rarely, sarcomas. The differentiated 
cancers retain the appearance and function (albeit at a lower level) of normal thyroid cells, 
and can, therefore, trap iodine. Radioiodide scintigraphy and therapy are based on the uptake 
of radioiodide by NIS in thyroid tissue, which can concentrate all isotopes of iodine.
1.3 – Standard Treatment of Thyroid Cancer
Management of differentiated thyroid cancer is well protocolised in most departments. 
For	an	example	of	this,	see	figure	three.
Total  or  near  total  thyroidectomy  is  the  mainstay  of  differentiated  thyroid  cancer 
management(10), (11). In addition to this, radioiodine has been a crucial component in the 
treatment of differentiated thyroid cancer for many years(12). Most differentiated thyroid 
cancers retain the ability to trap iodine, so radioactive Iodine-131 (131I) is initially used 
diagnostically	to	acquire	a	whole-body	scan,	for	dual	purposes:	to	screen	for	any	residual	4
thyroid tissue; and to identify metastatic sites. This practice has become controversial, 
however,	in	view	of	thyroid	stunning	(see	page	five).
Debate also exists as to whether post-thyroidectomy ablation therapy of the thyroid 
remnant by radioiodine is necessary in all patients. The argument in favour of this course 
of management states that ablation makes patient follow-up by thyroglobulin (a tumour 
marker secreted into the bloodstream) assessment more sensitive, allows early detection 
of metastatic disease by radioiodine scans, and reduces the theoretical risk of anaplastic 
transformation of any residual thyroid tissue in the neck. A study of 1355 patients(13)(14) 
showed that patients who had thyroid tumours greater than 1.5cm had a distinct survival 
advantage at 30 years if near total thyroidectomy followed by 131I ablation and lifelong 
thyroid hormone therapy was employed. 
The	 majority	 of	 clinicians	 and	 consensus	 guidelines	 now	 favour	 near	 total	 or	 total	
thyroidectomy followed by routine radioiodine thyroid ablation for anything other than 
very low risk patients, in view of the above data suggesting reduction in local recurrence 
and improvement in survival. 
By this practice, sensitivity of both scanning and therapy can be optimised, as uptake of 
radioiodide is based on the inherent ability of thyroid cancer cells to trap iodine. This 
ability is enhanced by a high level of the physiological stimulus thyroid stimulating 
hormone (TSH). Therefore, standard preparation for radioiodine scans and therapy is 
to induce hypothyroidism by cessation of thyroxine therapy for at least four weeks (15)(16).
Administered activities of 131I for thyroid ablation vary between 30 and 220mCi (1.1 and 
7.4GBq)(10).	Post-treatment	scans	are	performed	a	few	days	later	to	confirm	uptake	of	the	
radioiodine and identify any additional lesions not seen on the diagnostic scan.
Radioiodine also plays a valuable role in the treatment of recurrent or metastatic thyroid 
cancer. Following diagnosis of metastatic thyroid cancer, repeated therapeutic doses of 
radioiodine may be administered at four to six-monthly intervals, with activities ranging 5
between 5.5 and 11.1 GBq. While not curative therapy, this treatment strategy can be used 
repeatedly with  relatively little toxicity.
Immediate adverse effects of radioiodide therapy are of nausea and mild bone marrow 
suppression,  and  are  common  but  generally  mild  and  self-limiting.  Sialadenitis  and 
xerostomia may also occur. 
Thyroid stunning is a relatively recently appreciated phenomenon. A temporary reduction 
occurs in the ability of normal or metastatic malignant thyroid tissue to trap or retain 
131I, following prior administration of a diagnostic level of 131I. If that ability recovers 
to its initial level, the effect is transient and can be called ‘stunning’. If it never fully 
recovers, the effect is permanent and may be viewed as ‘partial ablation’(17). It appears 
that	any	scintigraphically	sufficient	amount	of	diagnostic	131I activity will induce thyroid 
stunning, even if therapeutic administration of  131I occurs within the following two to 
three days(18).
Thyroid stunning is important as it may cause a failure of radioiodine therapy, with all the 
attendant	consequences.	In	the	great	majority	of	thyroid	cancer	patients,	diagnostic	131I 
scintigraphy performed before 131I	therapy	reveals	no	unexpected	pathological	findings	
and	does	not	change	the	course	of	treatment.	The	main	justification	for	131I diagnostic 
studies is for dosimetric purposes. Some believe that, in view of stunning, diagnostic 
administration of 131I prior to radioiodine therapy is counter-productive and unnecessary, 
and if administered should be limited to a maximum of 4Gy absorbed dose by thyroid(18). It 
is not clear whether similar stunning phenomena would occur with the use of radioiodide 
therapy in malignancies other than thyroid. 
In conclusion, radioiodine therapy of thyroid cancer is extremely well established and, it 
is now recognised, exploits an endogenously expressed receptor, (NIS). There is a wealth 
of	safety	data	regarding	long-term	use	of	radioiodine	in	the	adjuvant	setting,	and	also	
regarding repeated use in the metastatic setting. The thyroid experience can be extrapolated 
to some degree for potential use in other malignancies such as metastatic breast cancer.6
Section 2 – Breast Cancer
2.1 – Incidence, Aetiology and Survival of Patients with Metastatic Breast Cancer
Breast cancer is the most common type of cancer in women in the UK, and is the second- 
most common cause of cancer-related death in women in the UK. Incidence rates vary 
considerably geographically, with the highest rates occurring in the developed world, and 
the lowest rates in Africa and Asia.  In the year 2000, there were more than one million 
new cases and approximately 373,000 deaths from breast cancer worldwide, with an age 
standardised death rate (ASR) of 12.51 (per 100,000). An ASR of 26.81 was recorded in 
the UK in 2000(19).
This situation remains true in Scotland, with breast cancer representing 27.5% of all 
female cancers. This accounted for 3,646 new diagnoses of breast cancer in 2002, and 
1,082 deaths due to breast cancer in 2004(1). The peak age of incidence is 63, and the 
majority	of	cancers	occur	in	women	aged	between	50	and	70	years	old,	hence	the	screening	
programme encompasses this age range. 
Risk factors for breast cancer include early menarche and late menopause, nulliparity, 
late	age	at	birth	of	first	child,	obesity,	strong	family	history,	BRCA1	and	2	carriage,	diet	
rich in fat, meat and alcohol, prolonged use of hormone replacement therapy (HRT), and 
exposure to ionizing radiation. Protective factors include prolonged breast feeding, intake 
of	fibre,	fruits,	vegetables	and	antioxidant	vitamins,	and	physical	activity.
Despite	a	reduction	in	mortality	figures	between	1994	and	2004	of	18%,	five-year	survival	
in Scotland remains only 80.2% for patients diagnosed between 1997 and 2001(1). When 
breast cancer recurs and becomes metastatic, it is treatable but not curable. Average 
survival is currently between one and two years, although some women may live with the 
disease for many years, particularly when they have hormone responsive disease, and/
or skeletal metastases only. It is clear that metastatic breast cancer remains a challenging 
clinical issue and novel treatments are required.7
2.2 – Molecular Biology of Breast Cancer: An Overview
There are a great number of molecular aberrations recognised in breast cancer cells, however, 
only a small number have become clinically relevant. These include overexpression of 
Her2/neu(20)(21)(22), and oestrogen and progesterone receptor expression(23)(24).
There is compelling evidence that breast cancers can develop in a multistep process, 
passing through a number of intermediate hyperplastic and neoplastic forms, each having 
a greater chance of transforming to a malignant state than the one before. The reliable 
recognition of these stages is of great value in learning more about the pathogenesis of 
breast cancer(25).
Oncogenes are recognised to play an important role in the development of breast cancer. 
These are genes whose activation and overexpression can contribute to the development 
of cancer. A striking example is the protooncogene c-erb-B-2 (Her2/neu), which encodes 
a	transmembrane	tyrosine	kinase	receptor.	It	has	been	shown	that	Her2/neu	is	amplified	
in approximately 20-30% of invasive breast cancers(21), resulting in more of the protein 
encoded by the gene being present; hence function of the protein is enhanced. The resulting 
phosphorylation of tyrosine residues initiates complex signaling pathways that ultimately 
lead to cell division. 
2.3 – Standard Treatment of Metastatic Breast Cancer
Prior	to	treatment	for	metastatic	breast	cancer,	confirmation	of	cytological	diagnosis	is	
indicated, followed by staging investigations to assess extent of disease. Once a diagnosis 
of recurrent or metastatic breast cancer has been made, an analysis of Her2/neu, oestrogen 
receptor (ER) and progesterone receptor (PR) expression in the primary breast cancer or 
metastases should be made. Thereafter, a patient’s therapy is “tailored” to correlate with 
the molecular expression of their malignant cells.
In hormone receptor positive disease, treatment may safely begin with endocrine therapy 
in	the	majority	of	cases(26),	but	ultimately	most	reasonably	fit	women	with	metastatic	breast	8
cancer will receive chemotherapy, either because they have hormone receptor negative 
disease or because their disease has become refractory to endocrine therapy(27).
Despite the availability of a great number of chemotherapeutic agents and combinations 
thereof, most women will ultimately require to cease treatment with these agents due 
to toxicity, or due to treatment failure consequent to acquired drug resistance. First line 
treatment in metastatic breast cancer is dependent on a number of factors, including 
fitness	for	aggressive	chemotherapeutic	regimens,	previous	exposure	to	agents	now	used	
increasingly	in	the	adjuvant	setting,	such	as	anthracyclines	and	taxanes,	and	hormonal	
status.	In	a	fit	patient	with	oestrogen	receptor	positive	disease,	hormonal	therapy	will	
typically be used. If a patient is ER negative, or requires a response to therapy more quickly 
than can be expected with hormonal therapy (weeks to months), then chemotherapy will 
be	employed	as	first-line	treatment.	The	choice	of	agent	will	depend	on	whether	the	patient	
has been exposed to chemotherapy as treatment for early breast cancer. This is increasingly 
the case. Anthracycline-based chemotherapy is preferred over non-anthracycline-based 
chemotherapy in the advanced disease setting(28). Taxanes	are	also	considered	for	first-line	
use(29).	For	less	fit	patients,	treatment	with	agents	such	as	capecitabine	or	vinorelbine	is	
frequently used(30)(31). 
Bisphosphonates  reduce  skeletal  complications,  delay  progression  of  existing  bone 
metastases and reduce the development of new lesions in patients with metastatic breast 
cancer. They act by interfering with osteoblast and osteoclast activity.  In breast cancer 
patients, bisphosphonate therapy is currently recommended for patients with radiographic 
evidence of bone destruction(32)(33)(34).
Radiotherapy, although standard treatment in early breast cancer, has little role to play 
in the management of metastatic breast cancer, other than to provide local control for a 
breast tumour, or to palliate brain or bone metastases. Radiotherapy is used frequently for 
localised bone pain with 60-70% of patients responding to treatment and about one-third 
achieving a complete response to pain(35).  There is no place currently for radioisotopes in 
the routine management of metastatic breast cancer.9
2.4 – Targeted Therapy of Metastatic Breast Cancer
“Targeted therapy” has become a frequently used expression in recent years, with numerous 
potential	novel	therapeutic	targets	being	identified	through	our	increasing	understanding	
of the biology of breast cancer development and progression.
The degree of media attention and clinical success witnessed in the management of chronic 
myeloid leukaemia (CML) and gastrointestinal stromal tumour (GIST) treatment with 
Imatinib (Glivec), has encouraged interest in a similar “magic” bullet for breast cancer(36). 
Imatinib	is	a	small	molecule	signal	transduction	inhibitor	that	specifically	targets	protein	
tyrosine kinases Abl, Arg (Abl-related gene), KIT, platelet-derived growth-factor receptor 
(PDGF-R)—and the bcr-abl fusion gene present in CML. Therapy with this agent induces 
dramatic and often durable clinical responses in most patients. In patients with CML, rates 
of complete response approach 100%(37). However, solid tumours display more complex 
genetic changes and heterogeneity as compared with haematologic malignancies, so this 
clinical scenario is not likely to be replicated as easily in breast cancer.
The earliest example of targeted therapy in breast cancer is hormonal manipulation, which 
includes ovarian ablation by surgery, radiotherapy or more recently drug therapy(38), and the 
anti-oestrogen drug Tamoxifen(24). Although it is a widely held perception that hormonal 
therapy is a “static” therapy and induces slow responses, this class of drugs actually 
accounts for the largest impact of all systemic therapies for breast cancer and leads to 
greater relative reductions in recurrence for early-stage disease than chemotherapy(39). 
More recently, a new class of hormonal agents in breast cancer has been developed and 
are now in regular clinical use in postmenopausal women. Of these aromatase inhibitors, 
Letrozole has shown advantage in disease-free survival in postmenopausal women when 
given	adjuvantly	following	tamoxifen	treatment(40).  
Chemotherapy also represents a form of targeted therapy in that the disruption of DNA 
(deoxyribonucleic acid) replication and cell division preferentially affects tumor cells 
over non- malignant tissue.10
Several biologic pathways have emerged over the past few decades which appear to be 
critical to carcinogenesis and can be exploited, or “targeted” for therapeutic purposes(41). 
A member of the Her gene family, encoding the epidermal growth factor receptor (EGFR) 
is recognised as being expressed in some cases of breast cancer. Its expression may be 
associated with a worse clinical outcome as well as estrogen-receptor (ER) negativity(42). 
Antibodies to EGFR are being assessed in clinical trials, although no activity has yet been 
reported in breast cancer. 
An example of a targeted therapy is Rapamycin. This inhibits the phosphorylation of 
mTOR (a pivotal downstream kinase that links stimuli from receptors to regulation of the 
cell cycle), thus blocking the downstream activation of various kinases and disrupting 
the cell cycle(43). CCI-779 is a rapamycin analogue which in a phase II trial involving 
chemotherapy refractory breast cancer patients showed some activity(44).
Cyclin-dependent kinases (CDKs) are proteins involved in various phases of the cell 
cycle that allow the cell to pass from a resting state, G0, into active cycling and mitosis. 
Flavopiridol	is	a	nonspecific CDK inhibitor, trials of which in combination with several 
chemotherapeutic agents are ongoing in breast cancer.
The c-myc oncogene encodes a nuclear protein that acts as a transcriptional regulator 
involved in cellular proliferation, differentiation, and apoptosis. It is overexpressed in up 
to 25% of breast tumors(45) and, in some series, has been associated with a worse prognosis 
or more aggressive clinical features(46). There also appears to be a role for myc in hormone 
responsiveness and chemotherapy resistance(47). Antisense trials targeting c-myc are in 
progress.
However, more clinically relevant than any of these examples, as outlined previously, 
Her2/neu is overexpressed in 20-30% of breast cancers, usually as a result of gene 
amplification.	This	oncogene	has	received	interest	due	to	its	recognised	association	with	
lymph node metastases, short relapse time, poor survival, and decreased response to 
endocrine therapy and chemotherapy. Her2/neu represents an excellent example of the 11
translation of basic science to clinical practice. In addition to the prognostic information 
that  Her2/neu  status  affords,  the  availability  of  the  humanised  monoclonal  antibody 
Trastuzumab (Herceptin) has been proven in a number of clinical studies to improve 
outcome in patients whose metastatic breast cancers overexpress Her2/neu, both when 
used	as	a	single	agent	first	line,	with	objective	response	rates	of	26%(48), and when used in 
combination with chemotherapy, where superior response rates (50% versus 32%), time to 
progression	(seven	months	versus	five	months),	and	median	survival	of	25	months	versus	
20 months were demonstrated(49). Also, there is early evidence of a role for Herceptin in 
the	adjuvant	setting.	The	HERA	trial(50) demonstrated a reduction in breast cancer events 
with a hazard ratio of 0.54. Cardiac toxicity was noted in 0.5% of women treated with 
Trastuzumab however, and there are concerns regarding the possible medium to long-
term cardiotoxic effects of this treatment.    
It	may	never	be	possible	to	find	a	genuinely	specific	breast	cancer-targeted	therapy.	Any	
drug	developed	that	targets	a	specific	genetic	abnormality	is	likely	to	be	practically	useful	
in only a limited number of patients, and resistance will almost certainly develop over time. 
However, such therapies can play a valuable role in tackling breast cancer, and it is likely 
that drugs such as Trastuzumab will increasingly be used in combination therapies.
Thus, it can be seen that any effective novel approach to metastatic breast cancer therapy 
is to be welcomed.12
Secion 3 – Radionuclides
3.1 – General Use
Nuclear medicine involves the use of unsealed radioactive sources to deliver radiation to 
tumours or target organs selectively. The exact mechanism of action is poorly understood, 
but involves delivery of low dose rate radiation, usually involving emission of alpha or beta 
particles,	or	an	Auger	electron.	The	basis	for	successful	radionuclide	therapy	is	sufficient	
uptake and prolonged retention of the radiopharmaceutical in the target tissues.
For benign diseases such as thyrotoxicosis and arthritis, radionuclide therapy provides a 
valuable alternative to surgery or medical therapy. In cancer treatment, it may be used as 
part of a therapeutic strategy with curative intent, such as in thyroid cancer therapy, or for 
disease control and palliation, for example in prostate cancer. Toxicity is generally limited 
to the haemopoietic tissues and few, mild side-effects are observed. It is generally accepted 
that long-term consequences are no greater than those associated with chemotherapy or 
external beam radiotherapy.
3.2 – Applications of Radionuclides in Benign Disease
One of the oldest and still most widely used applications of radionuclide therapy is 
Iodine-131 (131I)	for	thyrotoxicosis.	Long-term	follow-up	studies	have	confirmed	the	
safety of this treatment. The treatment is safe and cost effective, but causes permanent 
hypothyroidism in almost all patients treated for hyperthyroidism, most markedly those 
with Graves’ disease(51)(52).  In general, thyroid function returns to normal within two to six 
months after treatment, and hypothyroidism can develop within four to 12 months. 
The	intra-articular	administration	of	radiolabelled	colloids	such	as	the	pure	β	emitter	
Yttrium-90 (90Y) citrate and Rhenium-186 are effective in more than 60% of patients with 
rheumatoid arthritis and other arthritic disease(52)(53)(54).
3.3 – Applications of Radionuclides in Malignancy
Radioactive phosphorus, in the form of 32P orthophosphate (32P), has been in use since 13
the 1930s for the treatment of myeloproliferative disorders such as polycythaemia vera 
and essential thrombocythaemia.  32P is a pure ß-emitting radionuclide with a physical 
half-life of 14.3 days. Acting by incorporation of radiophosphorus into the DNA of 
rapidly proliferating cells, leading to DNA damage, 32P therapy may induce remission 
and prolong survival in these diseases(52)(55). Because of its strong incorporation into 
various phosphate-containing intracellular constituents, including DNA and RNA, and 
the potential long-term consequences of this, it is no longer in widespread use. However, 
as 32P is the only radionuclide that can be administered orally, it is extremely useful in 
many underdeveloped countries.
31I-m-iodobenzylguanidine (MIBG) is used in the treatment of neural crest tumours. 
Structurally similar to norepinephrine, MIBG is taken up by cells of neural crest origin, 
via the cell membrane and neurosecretory storage granules in the cytoplasm. Active 
uptake leads to retention of 131I-MIBG in neural crest tumours, resulting in high tumour/
non-tumour	ratios.	Radioactively	labeled	MIBG	was	first	used	in	the	early	1980s	to	image	
these tumors. More than 90% of phaeochromocytomas and neuroblastomas, around 35% 
of medullary thyroid carcinomas, and 70% of carcinoid tumours concentrate MIBG, are 
susceptible to treatment of this type(52).  
Strontium is an element that behaves biologically like calcium. It localises in bone, mainly 
in areas of osteoblastic activity(56).  89Sr has a relatively long physical half-life of 50.5 
days and emits only a ß-particle. After intravenous administration, 89Sr is concentrated 
in bone in proportion to local osteoblastic activity. Its use was revived in the 1980s after 
a long period of redundancy for treatment of painful bony metastases in prostate cancer. 
Multicentre-controlled studies in metastatic prostate cancer have shown that 89Sr is as 
effective as radiotherapy and that it may delay the onset of pain at new sites(57).
Samarium-153 (153Sm), a nuclide with a physical half-life of 1.9 days, is a beta emitter. A 
phosphonate-samarium complex concentrates in the skeleton, in proportion to osteoblastic 
activity. About 65% of the dose remains in the skeleton(56). 153Sm is the most widely used pain 
palliation radiopharmaceutical agent in the United States, mainly due to its ease of use.14
Rhenium-186 (186Re) has a physical half-life of 3.7 days and emits a ß-particle. A study by 
Sciuto et al. with 186Re showed overall pain palliation of 92% in breast cancer patients(58). 
The  tumour-to-bone  marrow  absorbed	 dose	 ratio	 was	 14:1,	 suggesting	 its	 clinical	
relevance in patients with compromised bone marrow reserve. Several studies reported 
the	safety	and	efficacy	of use of 186Re in bone pain palliation. The maximum tolerated 
administered activity of 186Re in patients with metastatic breast cancer was found to be 
2,405 MegaBequerels (MBq) with thrombocytopenia as dose-limiting toxicity(59) and a 
response rate of 77% has been reported(60).
Although external beam radiotherapy is the mainstay in the management of malignant 
bone	pain,	its	overall	efficacy	for	pain	control	is	from	60-90%(61)(62)(63), no better than 
radionuclides. Interestingly, a recent Cochrane review showed that there is no difference 
between the degree of palliation achieved by external radiation therapy treatment versus 
radionuclide-based therapy(64). Also, if multiple lesions require external beam radiotherapy, 
the side effects, in particular myelosuppression, limit the dose that can be delivered. It 
is well recognised that the pain in patients with multiple bony metastases has a tendency 
to move site on an almost daily basis, rendering external beam radiotherapy a somewhat 
impotent treatment modality. Hemibody radiation therapy has been used in patients with 
widespread	painful	lesions,	but	can	lead	to	significant	toxicity. In contrast, radionuclides 
can ablate both symptomatic and asymptomatic lesions, with minimal toxicity.
Radionuclides also offer other advantages in comparison with external radiotherapy. 
Radionuclide therapy such as strontium does not require special or costly equipment and 
thus is suitable for most hospitals with outpatient-based clinics, adequate laboratories, 
and basic radioactive shielding facilities. In addition, some studies in prostate cancer 
reveal an economic advantage to the addition of radionuclides to standard management 
with external beam radiotherapy(65)(66).
3.4 – 131I-iodine
Most radionuclide therapy in clinical practice today is with 131I. Its physical half-life is 
eight	days	and	the	majority	of	its	energy	is	emitted	as	non-therapeutic	gamma	rays.	This	15
requires that patients are isolated in shielded rooms for several days. Only one-third of the 
energy is emitted as beta rays, contributing directly to the therapeutic effect(52).
3.5 – Pertechnetate
Pertechnetate (99mTcO4) has ionic characteristics in common with iodide. Pertechnetate 
behaves similarly following intravenous administration, but has a practically advantageous 
shorter half-life of six hours. In addition, it is relatively inexpensive and readily available. 
It is therefore widely used in standard diagnostic imaging procedures. Pertechnetate is 
trapped,	but	not	organified	in	the	thyroid,	and	is	frequently	used	as	an	alternative	to	iodide	
in thyroid diagnostic studies.
3.6 – Use of Radionuclides Diagnostically in Breast Cancer
Bone scintigraphy using Tc99m Methylene disphosphonate has for many years been a 
widely used screening method for diagnosis and monitoring of bone metastases in most 
types	of	malignancy.		The	uptake	depends	on	both	local	blood	flow	and	osteoblastic	
activity. Osteoblastic response is secondary to osteoclastic bone resorption induced by the 
metastatic tumour itself. It is this osteoblastic response that is necessary for metastases to 
show increased activity on bone scan, but this is a relatively slow process and may require 
several weeks before a lesion can be visualised on bone scan.
Other than in this diagnostic capacity, however, radioisotopes have thus far had only a 
minor role in the routine management of metastatic breast cancer.
3.7 – Use of Radionuclides Therapeutically in Breast Cancer
The	majority	of	patients	with	metastatic	breast	cancer	affecting	bones	have	more	than	
one involved bony site. The administration of a radiopharmaceutical systemically has the 
potential to treat multiple metastases simultaneously.
In comparison to prostate cancer, the body of evidence regarding therapeutic use of 
radioisotopes in breast cancer is scarce. Theoretically, pain palliation in breast cancer 
could show unique features, as the microenvironment of bone metastases is quite different, 16
with prostate cancer having a prevalently osteoblastic structure and breast cancer a lytic 
or mixed pattern. There may be a difference in how well radioisotopes localise in these 
areas.
Radioactive  isotopes  of  strontium  and  phosphorus  have  been  most  extensively  used 
in treating breast cancer, as it was recognised that these elements were preferentially 
incorporated into the sites of all bone metastases at rates up to 25 times greater than they 
were in normal bone(67).
Sciuto et al performed a randomised study in patients with metastatic breast cancer, 
comparing treatment with Rhenium-186 and Strontium-89(58). The results demonstrated 
that both 89Sr and 186Re are effective in palliation of painful breast bone metastases without 
significant	differences	in	the	overall	response	rate	and	in	the	degree	of	response.
In summary, radioisotopes are extensively used in the management of benign and malignant 
disease. There is currently no place for use of radioisotopes in the standard management of 
metastatic breast cancer, although there are theoretical advantages of this type of therapy 
over external beam radiotherapy and chemotherapy. Radioisotope treatment of metastatic 
breast cancer, if feasible, would be a valuable addition to the armamentarium of therapies 
against metastatic breast cancer.17
Section 4 - Sodium Importer Symporter (NIS)
4.1 Characterisation and function of NIS
THE Na+/I−	symporter	(NIS)	is	an	integral	plasma	membrane	glycoprotein,	first	identified	
in the thyroid gland, where NIS mediates the active transport of I− into the thyroid 
follicular cells. This is a preliminary step in the biosynthesis of thyroid hormones T3 and 
T4 (tri-iodothyronine and thyroxine respectively). These hormones play a vital role in 
metabolism	and	growth,	most	significantly	of	the	nervous	system.	NIS	cotransports	one	
iodide ion against its electrochemical gradient, using the inwardly directed Na+ gradient 
generated by the Na+/K+ adenosinetriphosphatase (ATPase). The NIS receptor is blocked 
by the Na+ K+ ATPase inhibitor ouabain, in addition to competitive inhibitors, such as 
thiocyanate (SCN−) and perchlorate (ClO4
−)(68).
NIS is also expressed endogenously in a number of tissues, which include salivary glands, 
gastric	mucosa,	and	lactating	mammary	gland.	The	functional	significance	of	NIS	in	the	
gastric mucosa and salivary glands is unknown. However, it is postulated to be related to 
antimicrobial activity. Conversely, in the lactating mammary gland, it is clear that NIS 
functions to mediate the translocation of I− into the milk, making this available for the 
newborn to synthesize his own thyroid hormones(69)(70).
4.2 - Isolation of the NIS gene
cRNAs synthesized in vitro from a rat thyroid-derived cell line (FRTL-5) complimentary 
deoxyribonucleic	acid	(cDNA)	library	were	microinjected	into	Xenopus	laevis	oocytes	
and	assayed	for	NIS	activity.	A	single	positive	clone	was	identified,	allowing	isolation	of	
the (cDNA) encoding rat NIS(71).  The subsequently cloned human NIS gene(72) was found 
to be 87% homologous to the rat gene, although human NIS contains 20 additional amino 
acids in the C-terminal region. The human NIS (hNIS) gene is located on chromosome 
19p12-13.2  encoding  a  glycoprotein  of  643  amino  acids,  with  a  molecular  mass  of 
approximately 70-90 kDa. The coding region of hNIS contains 15 exons interrupted by 
14 introns and codes for a 3.9kb mRNA(73).18
4.3 Development of NIS Antibodies
Antibodies	were	first	generated	by	Levy	et	al	in	1997(74)	using	the	defined	sequence	of	the	
C-terminal peptide (amino acids 603-618). These antibodies have allowed for development 
of immunohistochemical techniques, to detect NIS protein in a wide variety of tissues.
4.4 Application of NIS-based Research in Breast Cancer
The seminal paper in clinical NIS based research was published in Nature Medicine in 
2000(75). This group examined NIS expression in both animal and human tissue. Firstly, 
it was shown that lactating mice took up radioiodide into their mammary tissue. The 
radioisotope was concentrated more than 6000% in milk compared with its level in blood, 
with saturation occurring at about two hours. Also, membrane immunostaining for NIS 
protein was seen in rat thyroid, stomach and lactating mammary tissue. Hormonal regulation 
experiments showed that in the lactating rat, a complex interplay of hormones controlled 
NIS expression. In addition, in vivo scintigraphic imaging of experimental mammary 
adenocarcinomas in nongestational, nonlactating female transgenic mice carrying either 
an activated Ras oncogene or overexpressing the Neu oncogene demonstrated pronounced, 
active,	specific	NIS	activity	that	was	inhibited	competitively	by	perchlorate.	
Tissue specimens were examined by immunohistochemical (IHC) analysis using two 
polyclonal	antibodies	(Ct-1	and	Ct-2)	and	one	monoclonal	NIS-specific	antibody.	By	
immunohistochemistry, Tazebay and co-workers showed further that 87% of 23 human 
invasive breast cancers and 83% of 6 ductal carcinomas in situ expressed NIS, compared 
with  only  23%  of  13  extratumoural  samples  from  the  surrounding  non-malignant 
breast	tissues.	Even	more	significantly,	none	of	the	eight	“normal”	breast	samples	from	
reductive  mammoplasties  examined  expressed  NIS.  The  same  group  examined  the 
immunohistochemical	profile	of	NIS	in	thyroid,	breast,	and	other	carcinomas	using	high-
density tissue microarrays and conventional sections(76). Validating the use of microarrays, 
they	analysed	371	breast	specimens,	and	the	results	were	in	concordance	with	findings	
stated	previously:	NIS	expression	was	observed	in	whole	tissue	sections	in	76%	of	
invasive	breast	carcinoma	and	88%	of	ductal	carcinoma	in	situ	samples.	The	majority	of	19
normal breast cores were negative (87%), as were 70% of normal/nonproliferative samples 
analysed. Plasma membrane immunoreactivity was observed in gestational breast tissues, 
and in some in situ ductal carcinomas and invasive ductal carcinomas.
These studies demonstrate the presence of NIS protein in breast cancer cells, but provide 
no functional information. Moon demonstrated that the postulated correlation between 
NIS	expression	and	uptake	of	radioiodide	did	hold	true	in	primary	human	breast	cancers:	
25 breast cancer patients were examined by scintigraphy and active uptake by the tumours 
was seen in those four patients whose tumours had comparatively higher levels of NIS 
mRNA(77). Min et al showed that 80% (eight out of 10) of patients with positive NIS 
immunostaining in a thyroid malignancy responded to radioiodine therapy with 131I for 
metastatic disease(78), whereas those with negative immunostaining responded poorly.
The above literature suggested that selective targeting of NIS positive breast cancer cells 
might be feasible. In 2004, Wapnir et al published data on 27 patients with metastatic 
breast cancer who were recruited into a clinical study designed to test this theory(79). 
Twenty-three of these women had their samples analysed by immunohistochemistry. All 
patients	also	had	scintigraphy	performed.	The	first	seven	patients	had	imaging	performed	
using pertechnetate; thereafter patients were scanned with iodide to allow dosimetry 
studies to be done. An attempt was made to suppress background thyroid activity using 
Tri-iodothyronine orally in about half of the patients. Of the 23 samples analysed for NIS 
protein	expression,	eight	demonstrated	NIS	significantly	(34.8%).	Of	these	eight	women,	
two had positive uptake on their scans. This suggests that the number of patients who 
have NIS positive breast cancers that actively uptake may be less than previously thought. 
Thyroid dosimetry was performed in three patients. By extrapolation, it was estimated 
that the potential dose to a NIS avid lung metastasis in one patient would be 30Gy with 
tolerable doses to thyroid and whole body.
Arturi demonstrated hormonal regulation of expression of NIS in an ER positive human 
mammary adenocarcinoma cell line MCF-7, where uptake of iodide was affected by 
insulin, IGF1/11 and prolactin(80).20
Kogai and colleagues reported an increase in NIS messenger ribonucleic acid (mRNA), 
NIS protein, and I− uptake activity by ninefold, in MCF-7 in response to all trans-retinoic 
acid (ATRA) treatment(81). Trans-retinoic acid is a well-recognised differentiation agent. 
This suggests that expression of NIS in breast cancer has the potential to be manipulated 
to improve therapeutic outcome, in much the same way thyroid cancer patients have their 
thyroid uptake maximised by TSH stimulation.
Helguera showed that while I− uptake is governed by NIS in breast cancer cells, I2 uptake 
can be seen to be independent of NIS expression(82). It is suggested that I2 uptake may be 
mediated by a common transporter in mammary and non-mammary cells.  
Knostman has recently shown that the discrepancy seen between NIS expression at IHC, 
and functional uptake of radioiodide may be explained by the presence of activation of 
the phosphatidylinositol-3 kinase (PI3K) protein in breast cancer cells(83). This protein 
seems	to	interfere	with	NIS	cell	surface	trafficking	leading	to	localisation	of	NIS	in	the	
cell rather than at the cell surface, perhaps explaining why NIS positive breast cancer may 
not always take up radioiodide. 
In	addition,	Tazebay	showed	that	suckling	hormones	could	positively	influence	NIS	
expression and functional activity in ovariectomised, lactating mice(75), albeit in a fairly 
complex manner. Oestrogen, prolactin and oxytocin in combination seemed to produce 
the maximal degree of NIS expression.     
The previously mentioned data suggests that NIS positivity and uptake in breast cancers 
may not be as high as initially thought in the Tazebay study. However, a level of 34.8% 
NIS expression compares well with the level of Her2/neu expression seen in breast cancer 
of 20-30%. In addition, as demonstrated above, there may exist methods for maximising 
expression and/or uptake by manipulation of hormonal levels, or administration of agents 
capable of stimulating NIS expression, such as All-trans-retinoic acid.  
4.5 Application of NIS based research in other cancers
Human and rat NIS have been introduced into several different tumour cell lines under 21
the control of various promoters using different transfer methodologies.
Shimura’s group reported transfection of the rat NIS cDNA into a malignant rat thyroid 
cell line (FRTL-Tc) that ordinarily does not show I− transport activity(84). The cell line 
that resulted from the transfection (Tc-rNIS), demonstrated a 60-fold increase in  125I− 
accumulation in vitro. Tumours formed with Tc-rNIS cells accumulated up to 27.3% of 
the total administered 125I−, showing an 11-fold to 27-fold increase in 125I− concentration, 
compared with non-transfected cells.
Mandell and colleagues imaged rat NIS-transduced A375 human melanoma tumours, 
which	accumulated	significantly	more	123I− than non-transduced tumours(85).
Kang and colleagues showed radioiodine uptake in a hepatoma cell line SK-Hep1 in vitro 
and in vivo after transfer of the human NIS gene(86).
Haberkorn used NIS-transduced prostate carcinoma cells to study in vivo biodistribution. 
In rat, the human NIS-expressing tumours accumulated up to 22 times more I− than 
contralateral transplanted wild-type tumours(87).
Boland used the AdNIS vector to transfect human SiHa cervix cancer cells and MCF-7 
breast cancer cells, in nude mice(88).	Uptake	in	AdNIS-injected	tumours	was	four	to	25	
times	higher	than	in	non-treated	tumours.	On	average,	11%	of	the	total	amount	of	injected	
125I− was recovered per gram of AdNIS-treated tumour tissue.
Nakamoto and co-workers established a novel breast cancer cell line, MCF3B, by stably 
transfecting NIS into the MCF-7 cell line(89). In a biodistribution study using MCF3B-
xenografted mice, high 125I− uptake (16.7%) was observed in the tumors one hour after 
injection.	In	addition,	high	tumour-to-normal	tissue	ratios	were	also	observed.
Although  it  has  been  demonstrated  by  the  above  groups  that  successful  NIS  gene 
transfer can occur to non-NIS expressing tumours, it was generally not possible to detect 
tumour	shrinkage	with	radioiodide	treatment,	probably	secondary	to	the	rapid	efflux	
of 131I observed. As the retention time of 131I− in these tumours was, at best, only a few 22
hours, this was not enough to deliver a radiation dose necessary to have any discernible 
therapeutic effect.
Boland proposed to increase the retention time of radioiodine in tumour cells by coupling 
the transfection of the NIS gene with thyroid peroxidase (TPO) – a gene involved in I− 
organification(90).	As	previously	stated,	the	organification	process	causes	radioiodine	to	
be retained within the thyroid for several days. This long retention time, similar to the 
physical half-life of 131I	(i.e.,	eight	days),	allows	a	significant	radiation	dose	to	be	delivered	
to tumour. In practice, the simultaneous transfection of both these genes can be hard to 
achieve. This group constructed a recombinant adenovirus encoding the human TPO gene 
under	the	control	of	the	cytomegalovirus	early	promoter	(AdTPO).	A	significant	increase	
in I−	organification	was	observed	in	SiHa	human	cervix	tumour	cells	coinfected	with	
AdNIS and AdTPO. The levels of I−	organification	obtained,	however,	were	too	low	to	
increase	significantly	the	I− retention time in the target cells. However, Huang showed 
that the transfection of non-small cell lung cancer (NSCLC) cells with both NIS and 
TPO genes did lead to increased radioiodide uptake and retention, as well as to enhanced 
tumour cell kill(91).
It	may	be	the	case	that	organification	is	not	required	in	all	tissues	to	allow	retention	of	
radioisotope in cells. This could explain the encouraging therapeutic results reported in 
various NIS-transduced tumours that do not organify I−. For example, Spitzweg stably 
transfected the human prostatic adenocarcinoma cell line LNCaP with NIS cDNA under 
the	control	of	the	prostate-specific	antigen	promoter(92). Xenografts in mice were treated 
with a single 3 mCi dose of 131I, and an average of 80-90% tumour volume reduction was 
seen in comparison with untreated controls. Following this, in vivo NIS gene transfer 
into	LNCaP	cell	tumours	was	performed	using	a	replication-deficient	human	adenovirus	
carrying the human NIS gene linked to the CMV promoter (Ad5-CMV-NIS). LNCaP 
xenografts showed a clear therapeutic response to 131I, with an average volume reduction 
in tumour size of 84%.
Dingli’s  group  recently  reported  131I−  therapy  of  NIS-transfected  myeloma  in  SCID 23
mice(93). They developed a self-inactivating lentivector controlled by an immunoglobulin 
promoter	 that	 resulted	 in	 efficacious	 and	 specific expression  of  a  NIS  transgene  in 
myeloma cells. A single dose of therapeutic 131I led to complete and durable remission. 
The result was impressive – all tumours in which 50-100% of the cells expressed NIS 
completely regressed two weeks after a single dose of 1 mCi 131I. Noting that treatment 
was  successful  even  though  hNIS  was  not  transduced  into  every  myeloma  cell,  the 
investigators postulated that non-transduced cells could be killed by electrons emitted by 
131I− from distant cells. Such emitted electrons can travel several cell diameters in vivo. 
This	is	a	classical	example	of	“cross-fire”	radiation	damage	by	β-emitters,	known	as	the	
“bystander effect”.
Carlin’s group demonstrated radioiodide uptake in a number of cell lines transfected 
with  human  NIS  including  glioma,  neuroblastoma,  and  ovarian  carcinoma.  Iodide 
accumulation was enhanced by factors of 10 to 41. It was also shown that spheroids 
of	NIS	expressing	glioma	cells	were	significantly	more	susceptible	to	lethal	effects	of	
I131 than monolayers. The multicellular three-dimensional spheroids are used to model 
avascular micrometastases. It was postulated that the increased cell kill seen was due to 
enhanced	efficiency	of	absorption	of	decay	energy	in	three-dimensional	cultures(94).
The above results provide strong evidence that radioiodide therapy may be effective in 
cancer cells that functionally express NIS. In addition, the ability to organify iodide does 
not seem to be an absolute requirement for these malignant cells. Many strategies have 
emerged to optimise NIS expression and uptake in cancer cells. It is recognised that a 
proportion of breast cancer cells express NIS endogenously, and this provides a sound 
basis to further explore the feasibility of radioiodide therapy in this disease.24
Section 5 – Conclusion of Introduction 
The Sodium Iodide Symporter represents a novel target in metastatic breast cancer. This 
receptor appears to be expressed endogenously in a high percentage of cases, allowing 
the prospect that patients could be treated with a radiohalide. There is a great wealth of 
experience regarding use of radioiodine in thyroid cancer, and this can be used to guide 
management of radionuclides in breast cancer.
The aim of this study was to assess the feasibility of radionuclide therapy in a group of 
patients with metastatic breast cancer, by analysing tissue samples for NIS expression and 
correlating this with uptake of radioiodine in their sites of metastatic breast cancer.   25
Chapter 2 – Material and methods
Section 6 – Immunohistochemistry 
6.1 – Materials
6.1.1 – General Equipment
DAKO Autostainer (Carpinteria, California, USA), slide racks (Azlon), ph tester sticks 
(Merck), pressure cooker (Vision biosystems), microwave (Proline), DAKO wax pen, 
magnetic	stirrer	(Flatspin	2),	humidified	chamber	(Biogenics),	slides	(Mcquilkin,	UK),	
coverslips (VWR, UK), Pertex permanent mounting medium glue (Cellpath,UK).
6.1.2 General Plastic and Glassware
Standard pipettes and droppers, glass dishes.
6.1.3 Chemicals and Reagents
Xylene, ethanol, Tris buffered saline (TBS), normal goat serum (NGS, 1ml in 19mls 
of TRIS, DAKO Cytomation kit), Diaminobenzidine (DAB, DAKO Cytomation kit), 
peroxidase  blocking  agent  (ChP,  DAKO  Cytomation  kit), Antibody  diluent  (DAKO 
Cytomation kit), haematoxylin, Scott’s tap water substitute (STWS), 0.5% copper sulphate 
in 0.9% N Saline, Tween (Sigma, UK), Antibody diluent (DAKO Cytomation kit).
6.1.4 – Buffers
Citrate	pH6	buffer	was	made	up	as	follows:	2.1g	citric	acid	was	dissolved	in	1000mls	
double-distilled (dd) H20, and 2 Molar (M) sodium hydroxide (NaOH) was added until 
the solution was pH6.
Ethylenediamine	tetra-acetic	acid	(EDTA)	pH8	buffer	was	made	up	as	follows:	H20,	
EDTA (Sigma, UK) and Trisma base (Sigma, UK).
Autostainer buffer made up of 3L Tris saline and 0.5mls/L Tween.
For	rabbit	anti-NIS	polyclonal	antibody	from	Prof	Jhiang,	Ohio:	solution	of	40mls	3%	26
Hydrogen	peroxide	(Sigma,	UK)	was	made	up	in	360mls	methanol,	Citric	acid	buffer:	as	
above, Tris buffered saline (TBS) and 1% bovine serum albumin (Sigma, UK)
6.1.5 – Tissue Samples and Antibodies
6.1.5.1 – Tissue and Cell Samples – Thyroid, Breast and Cultured Cell Sample
Archival tissue was obtained from patients with thyroid cancers, Graves disease and 
breast cancer. A cell block from UVW-NIS cells grown in culture (as described in section 
7.1.2) and spun down, was also prepared. 
6.1.5.2 – Primary Antibodies
Mouse anti-NIS monoclonal antibody was purchased from Chemicon, USA. The epitope 
is in the region 625-643 amino acids of human NIS.
Rabbit anti-NIS polyclonal antibody was a gift from Prof Jhiang, Ohio.
6.1.5.3 – Secondary antibody
DAKO Envision Secondary antibody (DAKO, USA).
6.2 – Methods
6.2.1 – Preparation of Tissue Samples
A protocol for the study was approved by the local ethical committee (LREC), and 
in accordance with this, written consent was obtained from all patients participating 
in  the  imaging  study,  to  allow  release  of  tissue  blocks  from  the  relevant  pathology 
departments.
For those outwith the imaging study, specimens were anonymised and therefore did not 
require	specific	consent	from	patients.
Tissue blocks of the original operative sample were obtained and 4µm sections were cut 
using a microtome and mounted on glass slides. 27
6.2.2 – Deparaffination of Tissue Samples
Slides	were	placed	in	racks	and	paraffin	removed	by	immersion	in	xylene	for	4	minutes	
(performed twice), and then three immersions in 100% ethanol for 1 minute each, followed 
by an immersion in methanol. The slides were thereafter kept moist in tap water at room 
temperature.
6.2.3 – Antigen Retrieval Procedure
The techniques generally involved the application of heat for varying lengths of time to 
formalin-fixed,	paraffin-embedded	(FFPE)	tissue	sections	in	an	aqueous	solution.	Citrate	 	
buffer of pH6.0 and Tris-EDTA pH8.0 are the most commonly used retrieval solutions and 
are suitable for most antibodies. Preliminary experiments to optimise the methodology 
demonstrated Tris-EDTA antigen retrieval provided superior staining to that using citrate.
1.5L of Tris-EDTA antigen retrieval mix was prepared using 1.5 litres of distilled water, 
0.555g	of	EDTA	and	0.825g	of	Trisma	base.	It	was	confirmed	that	pH	was	8.0	using	
disposable pH tester sticks. The solution was placed in a pressure cooker and heated in the 
microwave for 20 minutes. Once heated, slide racks were placed in the pressure cooker 
and	the	weighted	lid	put	in	place.	Slides	were	heated	for	five	minutes	at	full	pressure.	
Thereafter slides were allowed to cool at room temperature for 20 minutes. Following 
this, cold tap water was placed inside the pressure cooker to further cool the slides and 
prevent drying and slide racks were transferred (with care not to allow drying) into a glass 
dish containing TBS.
1.5L of Citrate antigen retrieval mix was prepared using 1.5 litres of distilled water, 2.1g 
citric acid in 1000mls ddH20. 2M NaOH was added to reach pH6.
6.2.4 – Loading of Reagents onto DAKO Autostainer
The DAKO Autostainer is an automated slide processing system (DAKO, California, 
USA) which was used to process samples.
Non-specific	background	staining	due	to	non-immunological	binding	of	specific	sera	to	28
specific	sites	within	tissue	by	hydrophobic	forces	was	blocked	by	normal	goat	serum	
(NGS) 200µL per sample for 20 minutes. Slides were then rinsed.
Primary antibody incubation was then performed at one in 1000 dilution with antibody 
diluent for 60 minutes, and then slides were rinsed.
Some	tissues	contain	endogenous	peroxidases	which	can	lead	to	non-specific	staining.	
Endogenous endoperoxidase staining was blocked with hydrogen peroxide 3% solution   
200µL	(DAKO)	for	five	minutes	and	slides	were	rinsed.
Secondary antibody was applied with 200 µL per sample for 30 minutes, and rinsed.
Diaminobenzidine	chromogenic	substrate	was	used-	200	µL	per	sample	for	five	minutes,	
then repeated once more. Upon oxidation, DAB forms a stable, brown, end-product at the 
site of the target antigen. Slides were rinsed and kept moist.
6.2.5 – Slide Counterstaining, Fixing and Mounting
Slides were placed in haematoxylin solution to counterstain nuclei for an appropriate 
amount of time (Haematoxylin stains nuclei dependent on the age of the solution, which 
degenerates with time, therefore there is a relationship between age of solution and length 
of time required to adequately counterstain), then washed in tap water. Slides were then 
blued	using	Scott’s	tap	water	substitute	as	follows:	immersion	in	STWS	for	2	minutes,	
or until slides were coloured blue. Slides were then rinsed in tap water and placed in 
0.5%	copper	sulphate	solution	for	5	minutes.	A	final	rinse	in	tap	water	was	followed	by	
dehydration in methanol for 1 minute, followed by 100% ethanol for 1 minute, four times. 
Slides were immersed in 100% xylene for 10 seconds three times. Finally, slides were 
mounted with coverslips manually with mounting medium.
6.2.6 Assessment of Staining by Light Microscopy
Slides	were	viewed	on	a	Leica	microscope	under	x10,	x20	and	x40	magnification.	First,	
the control slide was viewed to ensure adequate staining. Then each slide was viewed 
with the corresponding negative control to assess staining.29
6.2.7 – Manual Methods
The	deparaffination	and	antigen	retrieval	steps	were	performed	as	described	above.	Excess	
fluid	was	wiped	from	slides,	and	the	tissue	section	drawn	around	with	wax	pen.
Normal Goat Serum was added dropwise. Slides were incubated for 10 minutes at room 
temperature. Then, primary antibody (200µl) was dropped on sample slides and the same 
volume of antibody diluent on the negative slides. The slides were incubated overnight at 
2-8°C. The slides were washed in TBS using a magnetic stirrer for 5 minutes (changing 
TBS midway). 
The slides were blotted with absorbent paper, then peroxidase blocking agent was added 
dropwise, and slides were incubated for 5 minutes. The slides were washed twice in TBS 
solution for a total of 5 minutes using a magnetic stirrer. The slides were blotted with 
absorbent paper, then DAKO Envision Secondary Antibody was added dropwise onto 
the slides. Slides were incubated for 30 minutes. The slides were washed in TBS using a 
magnetic stirrer twice for a total of 5 minutes.
Slides	were	counterstained,	fixed	and	mounted	as	described	in	section	6.2.5.
6.2.8 – Antibodies
6.2.8.1 – Anti-NIS monoclonal antibody staining
Mouse  anti-NIS  monoclonal  antibody  was  purchased  from  Chemicon,  USA   
initially  in  2004.  The  epitope  is  in  the  region  625-643  amino  acids  of  human   
NIS. This was used with the DAKO Autostainer and manual methods as described in 
section 6.2.
6.2.8.2 Anti-NIS Polyclonal Antibody Staining
Rabbit anti-NIS polyclonal antibody was a gift from Professor Jhiang, Ohio, received in 
March 2006. 
The suggested protocol supplied by Professor Jhiang’s group was followed. 30
Briefly,	citric	acid	buffer	1L	was	heated	in	a	pressure	cooker	in	the	microwave	for	15	
minutes.
Deparaffination	and	rehydration	were	performed	as	described	in	section	6.2.2.
Endogenous	 peroxidase	 activity	 was	 blocked	 as	 follows:	 slides	 were	 soaked	 in	 3%	
Hydrogen peroxide in methanol for 5 minutes, and rinsed in distilled H20 for 1 minute 
twice.
Antigen	retrieval	was	performed:	slides	were	dipped	in	heated	distilled	H20	in	a	jar	10	
times gently and placed in citric acid buffer in a pressure cooker in microwave for 8 
minutes.	The	heated	jar	was	removed	and	cooled.	Tissue	was	blocked	as	described	in	
section 6.2.4. 
Slides were transferred into TBS and washed for 1 minute twice in magnetic stirrer. 2% 
Bovine serum albumin (BSA)-TBS was applied to the slides and they were incubated in 
a	humidified	chamber	for	1	hour	at	room	temperature.
Primary	antibody	incubation	was	as	follows:	the	primary	antibody	was	diluted	in	1%	
BSA-TBS, 1 in 1000. Excess blocking solution was blotted with paper. Dilute antibody 
was	applied	to	slides,	and	they	were	incubated	in	humidified	chamber	for	1	hour	at	room	
temperature.
Secondary	antibody	incubation	was	as	follows:	Envision	secondary	antibody	was	used.	
Excess primary antibody was drained, and slides were washed in TBS in magnetic stirrer 
for 1 minute three times. Excess TBS was blotted off with paper. The secondary antibody 
was	applied	to	slides	and	incubated	in	humidified	chamber	for	20	minutes	at	room	
temperature.
Signal	detection	was	performed	as	follows:	excess	secondary	antibody	was	drained,	and	
washed in TBS in magnetic stirrer for 1 minute three times. Excess TBS was blotted with 
paper.	DAB	was	applied	and	slides	incubated	in	humidified	chamber	for	10	minutes.	31
Slides were washed in distilled H20 three times for 1 minute.
Haematoxylin staining and clarifying, dehydration and mounting were performed as 
described in section 6.2.5.
Initial  staining  was  poor  in  terms  of  intensity,  using  differentiated  thyroid  cancer 
specimens as a positive control. The technique was optimised further by using a Graves 
thyroid specimen as a positive control. The suggested protocol was further improved 
by substitution of the manual process of antibody incubation outlined above with the 
standard DAKO protocol for antibody incubation, outlined in section 6.2.4. 
In the experiments using patient samples, the polyclonal antibody with standard EDTA 
protocol as described above using the DAKO Autostainer was used, as this produced 
less background staining and better staining of the positive control than the suggested 
protocol.32
Section 7 – RNA Extraction and Analysis from Cell Lines
7.1 – Materials
7.1.1 – General Equipment
5% CO2 from cylinder supply (Air Products PLC, Walton-on-Thames), Surrey Microscope 
(Olympus, model CK2). 
PCR machine - ABI 7700 Sequence Detection system (Perkin-Elmer Applied Biosystems, 
Foster City, USA). 
7.1.2 – Media and Chemicals
RPMI  -1640  (Sigma-Aldrich,  UK)  and  Minimal  Essential  Medium  (MEM,  Sigma-
Aldrich,  UK).  L-Glutamine  (Gibco,  Paisley,  UK),  Foetal  bovine  serum  (Autogen 
Bioclear), Fungizone (Gibco), Penicillin- Streptomycin (Gibco), Trypsin 0.5% Stock 
(Gibco), Phosphate Buffered Saline (PBS).
Beta-mercapto-ethanol	(Fisons	Scientific	Equipment,	Loughborough).
7.1.3 – Reagents and Kits
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) primers and probe, Oswel, UK.
NIS primers and probe, TAGN, UK.
RT-PCR	reagents:	(Roche,	UK)	5mM	MgCl,	5µl	10X	PCR	buffer,	dNTP	mix	(1mM	each	
nucleotide), 1 unit of RNAse inibitor, 2.5µM random hexamers and 2.5 units of MuLV 
Reverse Transcriptase.
Qiagen RNeasy RNA extraction kit, Cat Number 74104, Qiagen Ltd, West Sussex, UK.
7.1.4 – Agarose Gel Electrophoresis Equipment 
Agarose (Medford Ltd, Chesworth, UK), Tris-acetate-EDTA buffer (TAE) 40X stock 
solution diluted to 1X using distilled H20, Ethidium bromide (Sigma, UK), loading 33
dye, DNA 1KB ladder (Gibco -Cat.no. 1565-016, UK), electrophoresis tank (Anachem 
Bioscience), Gene	Genius	Bio	Imaging	system	(Synegene	Ltd.,	Beacon	House,	Nuffield	
Rd, Cambridge).
7.1.5 – Plasticware and Glassware
T75	flasks	(Iwaki	Ltd),	pipettes,	30	ml	universal	containers	(Sterlin	Ltd),	Olympus	slides	
and	coverslips,	BDH	Haemocytometer	(Weber	Scientific	International,	Marlborough	Rd,	
West Sussex).
7.1.6 – Cell Lines
UVW-NIS, a glioma cell line expressing NIS was designed by a member of the group and 
was	used	extensively	as	a	positive	control.	It	was	made	as	follows:	UVW	human	glioma	
cells were transfected with cDNA encoding the human NIS gene to create the NIS-6 
line(93).  Cells were maintained in Minimal Essential Medium, supplemented with 10% 
foetal bovine serum, fungizone, and penicillin/streptomycin. Cells were cultured at 37°C, 
in	a	T75	flask	in	5%	CO2.  
MCF7, a well recognised ER/PR positive human breast cancer cell line, derived from 
a pleural effusion, known to express NIS only at low levels(80) was obtained from the 
Department of Medical Oncology, University of Glasgow. Cells were maintained in 
RPMI Medium, supplemented with 10% foetal bovine serum, fungizone, and penicillin/
streptomycin.	Cells	were	cultured	at	37°C,	in	a	T75	flask	in	5%	CO2.	
T47D, an ER negative human breast cancer cell line, derived from a pleural effusion 
and not known to express NIS was obtained from the Department of Medical Oncology, 
University of Glasgow.  Cells were maintained in RPMI Medium, supplemented with 
10% foetal bovine serum, fungizone, and penicillin/streptomycin. Cells were cultured at 
37°C,	in	a	T75	flask	in	5%	CO2.  
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7.2 – Methods
7.2.1 – RNA Extraction and Analysis from Cell Lines
7.2.1.1 – Cell Culture and RNA Extraction
Cells were incubated at 37°C in 5% CO2 in culture media as described above. Media was 
changed after 24-72 hours.
Cells	were	trypsinised	every	three	to	five	days	once	confluent,	depending	on	rate	of	cell	
growth	as	follows:
Stock trypsin was diluted one in eight in PBS. Media was removed in the tissue culture 
hood.	10mls	PBS	was	added	to	each	flask,	to	wash	off	media.	This	was	shaken	gently	and	
discarded.	2mls	of	trypsin	was	added	to	the	bottom	of	each	flask,	and	shaken	gently.	Flask	
was placed in an incubator at 37°C for 5 minutes. Once cells had detached, 8mls of media 
was added to inactivate the trypsin. The 10mls solution was transferred to a universal 
tube. This was made into a cell suspension with a 10 ml syringe and an 18 gauge needle. 
This was passed through the needle three times, and placed back in the universal tube.
Cells  were  counted  using  a  haemocytometer  placed  under  a  microscope  using  X10 
magnification.
2.5 x 105	cells	were	then	placed	in	2	T75	flasks,	20mls	media	and	a	few	mls	5%	C02 added 
to	each	flask.	Flasks	were	kept	at	a	temperature	of	37ºC.
Total RNA was extracted from cell lines using the Qiagen RNeasy kit according to the 
manufacturer’s	instructions	and	evaluated	by	RT-PCR.	Once	cells	were	confluent,	they	
were trypsinised as described above, counted and centrifuged at 1500rpm for 4 minutes. 
Supernatant was discarded, and tissue was re-suspended in Buffer RLT (TMQiagen inc), 
from kit, but requiring addition of beta-mercapto-ethanol. The samples were vortexed and 
homogenised in a syringe with an 18 gauge needle. 70% ethanol was added to lysate and 
mixed by pipetting.35
Samples were applied to RNeasy mini-columns (TMQiagen inc) in 2ml collection tubes. 
Then,	samples	were	centrifuged	at	10,000rpm	for	15	seconds.	Thereafter,	flow-through	
was discarded.
700µl Buffer RW1 (TMQiagen inc) was added to each column, and the columns centrifuged 
at	10,000rpm	for	15	seconds.	The	tubes	with	flow-through	were	discarded.
Columns were transferred into new 2ml collection tubes, and 500µl Buffer RPE (TMQiagen 
inc) pipetted onto columns. The columns were centrifuged at 10,000rpm for 15 seconds. 
Flow-through was discarded.
Thereafter, 500µl Buffer RPE was added, and samples centrifuged for 2 minutes to dry 
off silica-gel membrane. Then, columns were transferred to new 1.5ml collection tubes.
30-50µl RNase free H20 was pipetted onto the gel membrane of the collection tubes, and 
centrifuged for 1 minute to elute RNA. Samples were labelled and frozen at -70°C.
7.2.1.2 – Analysis of RNA using RT-PCR
RNA obtained was used in a 2-step RT-PCR (Roche, UK) reaction using NIS primers to 
amplify any NIS present.
Standard RT-PCR was carried out under the following conditions. 1µg of total RNA was 
reverse transcribed in a 50µl reaction volume, containing 5mM MgCl, 5µl 10X PCR 
buffer, dNTP mix (1mM each nucleotide), 1 unit of RNAse inibitor, 2.5µM random 
hexamers and 2.5 units of MuLV Reverse Transcriptase.
The	RT	thermal	cycling	conditions	were	as	follows:	42ºC	for	15	minutes,	99ºC	for	5	
minutes	and	4ºC	for	5	minutes.
10µl	of	the	resulting	solution	containing	cDNA	template	was	added	to	an	amplification	
reaction	containing	a	final	volume	of	50µl	with	1µl	50mm	MgCl,	4µL	10X	PCR	buffer,	
32.75µl ddH2O, 2ng each of Forward and Reverse NIS primers, and 0.25ul Taq polymerase 
(2.5U/100ul).36
The	PCR	thermal	cycling	conditions	were	as	follows:	94ºC	for	3	minutes,	then	35	cycles	
of	94ºC	for	1	minute,	60ºC	for	1	minute	and	72ºC	for	1	minute. Primer sequences were 
designed from the published sequence for the human sodium iodide symporter (hNIS). The 
sense primer corresponded to bases 630-649 (5’-CTTCTGAACTCGGTCCTCAC-3’) of 
the human NIS sequence. The antisense primer was complementary to bases 1064-1083 
of  the  human  NIS  sequence  (5’-TCCAGAATGTATAGCGGCTC-3’).  These  primers 
generated a PCR product of 454 base pairs.
In  later  experiments,  a  NIS  sense  primer  corresponding  to  bases  696-715  (5’-
ACCTACGAGTACCTGGAGAT-3’) was used, with an antisense primer complementary 
to bases 814-832(AGCCCGGTCACTTGGTTCA-3’). These primers generated a NIS PCR 
product of 137 base pairs. This primer set was utilised as the use of potentially partially 
degraded	RNA	samples	necessitated	the	amplification	of	a	small	target	sequence.
A	 separate	 amplification	 reaction	 was	 performed	 as	 an	 internal	 standard	 using	 the	
housekeeping  gene  glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH).  Primer 
sequences were designed from the published sequence of human GAPDH. The sense 
primer corresponded to bases 77-95 (5’-GCATTGCTGATGATCTTGAGGC-3’) of the 
human GAPDH sequence. The antisense primer was complementary to bases 487-509 
(5’-TCGGAGTCAACGGATTTGG-3’). These primers generated a PCR product of 432 
base pairs.
The resulting PCR products were run on a 1% agarose gel. This was made by dissolving 2g 
of agar in 200mls TAE 1 X Buffer consisting of 0.04M Tris-Acetate and 0.001M EDTA at 
pH 8.3, and heating in the microwave for 2 minutes. When cooled, 10µl ethidium bromide 
was added with care and mixed. This mixture was poured into a gel mould and allowed 
to set with a comb in place. When set the comb was removed. The gel was placed in an 
electrophoresis tank and covered with TAE 1 X Buffer. 10µl DNA 1kb ladder was placed 
in the 1st well. 2µl loading dye was added to the 20µl PCR product, and 10µl placed in each 
well. The machine was turned to 100V and run for 30-45 minutes. The gel was viewed 
under ultraviolet light and photographed using Gene Genius Bio Imaging system.37
Section 8 – RNA Extraction and Analysis from Paraffin Embedded Tissue
8.1 – Materials
8.1.1 – Equipment
8.1.1.1 – General Equipment
Microtome (Leica), Heating block (Techne), waterbath (Thermo Shandon), rotating oven 
(Hybaid),  microcentrifuge,  cold  centrifuge,  large  centrifuge,  vortex  (Jencons),    PCR 
machine, Gilsons P1, P10, P200, P1000 (Gilsons, UK). 
8.1.1.2 – General Plasticware
Pipettes, eppendorffs, 30 ml universal containers (as before).
8.1.1.3 – Chemicals
Xylene,  100%  ethanol,  70%  ethanol,  50%  ethanol,  20%  ethanol, Trizol  (Invitrogen, 
Paisley), chloroform, isopropanol.
8.1.1.4 – Buffers
50 mM TrisHydroChloride (TrisHCL) (pH8) - made up of 0.444g Tris HCl (Sigma, UK) 
and 0.265g Trisma Base (Sigma, UK) in 100mls DEPC H20.
10%	SDS:	5g	Sodium	Deca	Sulphate	in	50	mls	DEPC	H20 (BDH, UK).
10mg/ml proteinase K (Sigma, UK).
8.1.1.5 – RNA extraction kits
Qiagen RNeasy kit (Qiagen Ltd, West Sussex, UK).
ZYMO Pinpoint kit (California, USA).
Purescript kit (Flowgen, Nottingham, UK).
Ambion kit (Recover All Nucleic Acid Total Isolation, catalogue no 1975, Ambion, 
Austin, Texas, USA).38
8.1.1.6 – RT-PCR kits and components
GAPDH primers and probe, ABI, UK.
NIS primers and probe, TAGN, UK.
Porphobilinogen deaminase Primers, Eurogentec Ltd, Winchester Hill, Romsey, UK.
Minelute	PCR	Purification	kit	(Qiagen,	UK).
GAPDH 1 Step method- ABI Multiscribe, ABI Probe/Primers GAPDH mix, ABI Universal 
mix, nuclease- free H20 (all Ambion), 2X Taqman mastermix (ABI)
NIS	and	GAPDH	2	Step:	5	X	RT	buffer	(Invitrogen,	Paisley,	UK),	0.1M	DTT	(dithiothreitol)	
(Invitrogen, Paisley, UK), 25mM dNTPs (Invitrogen, Paisley, UK), Random hexamers 
(Invitrogen, Paisley, UK), RTase (X10) (Invitrogen, Paisley, UK), 10µl Rnasin (Invitrogen, 
Paisley, UK), Murine Moloney virus (M-MLV) (Invitrogen, Paisley, UK).
PCR core kit for two-step method (Roche Applied Science, UK).
Rnase sprays (RNase zap, Ambion, UK)
Photospectrometer (Eppendorff Biophotometer)
PCR machine - ABI 7700 Sequence Detection system (Perkin-Elmer Applied Biosystems, 
Foster City, USA). 
8.1.1.7 – Agarose Gel Electrophoresis Equipment 
Agarose (Medford Ltd, Chesworth, UK), Tris-acetate-EDTA buffer (TAE) 100X stock 
solution diluted to 1X using distilled H20, Ethidium bromide (Sigma, UK), loading 
dye, DNA 1Kilobase ladder (Gibco –Catalogue number 1565-016, UK), electrophoresis 
tank (Anachem Bioscience), Gene Genius Bio Imaging system (Synegene Ltd., Beacon 
House,	Nuffield	Rd	Cambridge).39
8.1.1.8 – Nanodrop Equipment
Nanodrop ND-1000 (Ambion, UK).
8.1.1.9 – Taqman PCR Equipment 
ABI Taqman 7900HT, ABI one step RT-PCR kit. 
8.1.2 – Tissue Samples
Archival	 paraffin-embedded	 thyroid	 and	 breast	 tissue	 10-20µm	 thick,	 cut	 using	 a	
microtome and stored in eppendorff tubes at room temperature.
8.2 – Methods 
8.2.1 – Collection and Preparation of Tissue and Cell Samples
A protocol for the study was approved by the local ethical committee, and in accordance 
with this, written consent was obtained from all patients participating in the imaging 
study, to allow release of tissue blocks from the relevant pathology departments.
For those outwith the imaging study, specimens were anonymised and therefore did not 
require	specific	consent	from	patients.
Sections were cut using a microtome designated for PCR work, ranging from 1 x 10µm 
section	to	4	x	20µm	sections	depending	on	the	RNA	extraction	kit	specifications.
8.2.2 – Maintenance of RNAse Free Working Environment
Anti-RNAse sprays were used to clean the workbench and pipettes prior to their use. 
Pipettes were treated with UV light prior to use. A designated area was used for RNA 
work only to avoid contamination.40
8.2.3 – Extraction of RNA
8.2.3.1 – Extraction of RNA using Qiagen RNeasy kit
First,	paraffin	embedded	thyroid	samples	were	deparaffinated	as	follows.	Each	sample	
was immersed in 1000µl of 100% xylene in a 1.5ml microfuge tube, and incubated at 
room temperature for 30 minutes. The xylene was removed by pipetting and the step was 
repeated. The samples were centrifuged at 3000rpm for 5 minutes at room temperature. 
Each sample was immersed in 1000µl of 100% ethanol and incubated at room temperature 
for 2 minutes. The samples were centrifuged at 3000rpm at room temperature and the 
ethanol removed by pipetting. This step was repeated with 70%, 50% and 20% ethanol. 
Finally, 1ml double distilled H20 was added for 2 minutes, and samples were centrifuged 
at 13, 4000 rpm for 10 minutes, then H20 removed by pipetting. Samples were left at 37°C 
for 40 minutes to air-dry. Thereafter, instructions were followed as described in section 
7.2.1.2.
8.2.3.2 – Extraction of RNA using ZYMO kit
Thyroid	samples	were	deparaffinated	as	described	above.
20µl of RNA digestion buffer and 5µl proteinase K were added to tubes containing 
recovered tissue, mixed gently and incubated at 55°C for 4 hours. Tubes were centrifuged 
for 30 seconds. Then, 50µl of RNA extraction buffer was added to each tube and mixed by 
pipetting. Then, 75µl 100% ethanol was added to each tube and vortexed. The tubes were 
transferred to ZYMO spin columns and these columns placed in 2ml collection tubes. 
The columns and tubes were centrifuged at full speed for 1 minute. 200µl RNA wash 
buffer was added to each spin column and centrifuged at full speed for 1 minute. Another 
200µl of RNA wash buffer was added to each column and centrifuged. The columns were 
transferred into new 1.5ml tubes, and 10µl of RNA elution buffer, prewarmed to 60°C 
was added. Samples were labelled and frozen at -70°C.41
8.2.3.3 – Extraction of RNA using Trizol method
Fresh  20µm  sections  of  NIS  pellet,  thyroid,  reactive  node  and  breast  cancer  were 
deparaffinated	as	follows.	Samples	were	incubated	with	1ml	xylene	and	vortexed	for	a	few	
seconds. Then samples were centrifuged at 13,000 rpm for 5 minutes. Supernatant was 
removed	and	discarded.	1ml	100%	ethanol	was	added	and	this	step	repeated.	Nescofilm	
(a	clear	film)	was	placed	over	the	top	of	the	tubes	and	pierced.	Samples	were	vacuum	
dessicated	dry	for	5	minutes.	The	following	solutions	were	made	up:	-50	mM	Tris	HCl	
solution (pH8), made with 0.444g Tris HCl, 0.265g Trisma Base, 100mls DEPC H20 and 
10% SDS solution, made with 5g SDS in 50mls DEPC H20.
4.5mls TrisHCL mix was added to 0.5mls SDS mix in a universal container. 1ml of this 
mixture was added to 50µl Proteinase K (10µg/mL). Thereafter, 100µl of this mixture 
was added to each Eppendorf tube. Samples were incubated overnight at 37°C in a 
waterbath.
Samples were centrifuged at 13,000rpm for 6 minutes at 4°C.  Supernatant was removed 
and samples transferred to RNase free Eppendorfs. Samples were mixed by pipetting.
800µl Trizol was added to each sample and pipetted. Samples were incubated at room 
temperature for 5 minutes.
160µl chloroform was added to each sample and shaken vigorously for 15 seconds, and 
then samples were incubated at room temperature for 3 minutes. Thereafter, samples were 
centrifuged at -4°C at 13,000rpm for 15 minutes.
The aqueous phase was removed with care, and transferred to RNase free tubes.
RNA was precipitated with 500µl isopropanol and mixed. Samples were incubated at 
-20°C for 1 hour.
Following this, samples were centrifuged at -4°C at 13,000rpm for 20 minutes.42
Supernatant was removed and discarded. The visible pellet was washed twice with 0.5-
1ml 100% ethanol, by inversion three times.
Samples were centrifuged at -4°C at 13,000rpm for 5 minutes.
All supernatant was removed. The pellet was air-dried for 1 hour.
Then samples were re-suspended in 20µl DEPC H20, vortexed for a few seconds, and 
then centrifuged for 15 seconds at 13,000rpm. Samples were placed in heating block at 
55°C for 5 minutes. Finally, samples were centrifuged for 15 seconds at 13,000rpm, and 
then stored at -20°C.
8.2.3.4 – Extraction of RNA using Purescript Kit.
Fresh 10µm sections of NIS pellet, thyroid, reactive node and breast cancer were cut 
using	a	microtome.	Sections	were	then	deparaffinated	as	follows.	500µl	100%	xylene	
was added to each tube. Tubes were then incubated for 5 minutes at room temperature 
mixing constantly. Samples were then centrifuged at room temperature at 13,400 rpm 
for 3 minutes. The xylene was removed by pipetting. This step was repeated twice. 
Thereafter, 500µL 100% ethanol was added to each tube. Tubes were incubated for 5 
minutes at room temperature with constant mixing. Samples were centrifuged at room 
temperature at 13,400 rpm for 3 minutes. The ethanol was removed and discarded. This 
step was repeated once.
Then, 300µl cell lysis solution was added to each tube, and the samples were homogenised 
with a tube pestle 20 times. 1.5µl fresh proteinase K (20mg/ml) was added to each tube, 
and the tubes inverted 25 times. Samples were incubated whilst constantly mixing at 
55°C in a rotary hybridization oven overnight.
Thereafter, samples were cooled to room temperature.
100µl protein-DNA precipitation solution was added to lysate in each tube, and inverted 
10 times. Samples were placed on ice for 5 minutes. Then, samples were centrifuged at 
13,400 rpm at room temperature for 3 minutes. The tissue was thus tightly pelleted.43
The supernatant from each tube was pipetted into clean 1.5ml eppendorff tubes with 
300µl isopropanol and 0.5µl glycogen (20mg/ml). Samples were mixed by inverting 50 
times.
Then, samples were incubated at -20°C for 1 hour. Samples were centrifuged at 13,400 
rpm at 4°C for 3 minutes.
Supernatant was removed and discarded, and tubes were drained on absorbent paper. 
300µl of 70% ethanol was added to each tube, and inverted 5 times.
Samples were centrifuged at 13,400 rpm for 1 minute at 4°C. Ethanol was removed and 
discarded. This step was repeated once.
Then tubes were inverted and drained on absorbent paper, and air-dried for 15 minutes.
25µl of RNA hydration solution was added to each tube, and incubated on ice for 1 
hour.
Samples were labelled and stored at -70°C.
8.2.3.5 – Extraction of RNA using Ambion Kit
The Ambion (Austin, Texas) kit was used. 4 x 20µm sections were cut using a microtome.
First,	sections	were	deparaffinated.	Each	sample	was	immersed	in	1000µl	of	xylene	in	a	
1.5ml microfuge tube, vortexed for a few seconds and then centrifuged at 13,400rpm for 
3 minutes.
Then xylene was removed by pipetting with care.
Samples were washed twice with 100% ethanol. This involved adding 1 ml ethanol and 
vortexing and centrifuging as with xylene.
Following this, all ethanol was removed by pipetting, and left to air-dry for 15 minutes on 
tissue paper with top open. Digestion was performed by adding 400µl digestion buffer and 44
40µl proteinase, placing in rotor oven for 3 hours at 50°C. Once digestion was complete, 
samples were stored at -20°C.
Nucleic acid isolation was then performed. 480µl Isolation Additive was added to each 
sample and vortexed to mix. Then 1.1ml 100% ethanol was added to each sample and 
mixed	by	pipetting.	A	filter	cartridge	was	placed	in	each	collection	tube,	and	700µl	of	the	
sample/ethanol	mixture	was	pipetted	onto	the	filter	cartridge.	Samples	were	centrifuged	
at	10,000rpm	for	60	seconds	to	pass	the	mixture	through	the	filter.	The	flow-through	was	
discarded,	and	the	filter	cartridge	re-inserted	into	the	same	collection	tube.	This	process	
was repeated until all the sample had passed through (three passes).
700µl of Wash 1 was added to each Filter Cartridge, and centrifuged for 60 seconds at 
10,000rpm.	The	flow-through	was	discarded,	and	the	filter	cartridge	re-inserted.
500µl	of	Wash	2/3	was	added	to	the	filter	cartridge,	and	centrifuged	for	60	seconds	at	
10,000rpm.	The	flow-through	was	discarded	and	the	filter	cartridge	re-inserted	into	the	
same collection tube. The assembly was centrifuged for 30 seconds to remove residual 
fluid	from	the	filter.
6µl of 10x DNase buffer, 4µl of DNase and 50µl of nuclease-free water were added to 
each	filter	cartridge,	as	a	master	mix.	The	tubes	were	capped	and	incubated	for	30	minutes	
at room temperature.
700µl	of	Wash	1	was	added	to	each	filter	cartridge	and	incubated	for	60	seconds	at	room	
temperature.	Samples	were	centrifuged	at	10,000rpm	for	30	seconds.	The	flow-through	
was	discarded	and	the	filter	cartridge	re-inserted	into	the	same	collection	tube.
500µl	 of	Wash	 2/3	 was	 added	 to	 each	 filter	 cartridge.	 Samples	 were	 centrifuged	 at	
10,000rpm	for	30	seconds.	The	flow-through	was	discarded	and	the	filter	cartridge	re-
inserted into the same collection tube. This process was repeated once.
The cartridges were transferred to fresh collection tubes. 30µl of pre-warmed nuclease 
free	water,	heated	to	95°	C	was	applied	to	the	centre	of	each	filter.	Samples	were	incubated	45
at room temperature for 1 minute, and then were centrifuged for 1 minute at 13,000 rpm. 
This process was repeated with a second 30µl of water to increase the eluate to 60µl.
Samples were stored at -80 ° C.
8.2.4 – Analysis of RNA by RT-PCR
In the case of the Qiagen and ZYMO methods, RT-PCR was performed as described in 
section 7.2.1.2.
In the case of the Trizol and Purescript methods, an internal housekeeping gene found 
in all human cells and involved in haem biosynthesis - Porphobilinogen deaminase was 
used. This was the standard housekeeping gene used at that time at the GRI lab where this 
work	was	done.	Primers	were	obtained	from	Eurogentec.	Details	were	as	follows:
The	 forward	 primer	 was	 PBDG	 F4,	 which	 had	 a	 sequence	 as	 follows:	  
5’GACCATGCAGGCTACCATCC  3’.  The  location  of  the  base  pair  was  906-925 
(inclusive), exon 13.
The	 reverse	 primer	 was	 PBDG	 R1	 with	 a	 sequence	 as	 follows:	  
5’AACTGTGGGTCATCCTCAGG  3’.  The  location  of  the  base  pair  was  952-
971(inclusive), exon 14.
The amplimer size of the F4/R1 product was 65 base pairs.
An	 additional	 forward	 primer	 F3	 with	 a	 sequence	 as	 follows:	
5’AAGGACCAGGACATCTTGGA3’ was used which detected an amplimer size of 265 
base pairs. A NIS positive transfectant UVW-NIS was used as a positive control in all 
described reactions.46
8.2.5 – Assessment of RNA Quality
8.2.5.1 – Assessment of RNA Quality by Agarose Gel Electrophoresis
The resulting PCR products in the case of the Qiagen and ZYMO methods were run on a 1% 
agarose gel. This was made by dissolving 2g of agar in 200mls TAE 1 X Buffer consisting 
of 0.04M Tris-Acetate and 0.001M EDTA at pH 8.3, and heating in the microwave for 
2 minutes. When cooled, 10µl ethidium bromide was added with care and mixed.  This 
mixture was poured into a gel mould and allowed to set with a comb in place. When set 
the comb was removed. The gel was placed in an electrophoresis tank and covered with 
TAE	1	X	Buffer.	10µl	DNA	1kb	ladder	was	placed	in	the	first	well.	2µl	loading	dye	was	
added to the 20µl PCR product, and 10µl placed in each well. The machine was turned to 
100V and run for 30-45 minutes. The gel was viewed under UV light and photographed 
using Gene Genius Bio Imaging system.
8.2.5.2 – Assessment of RNA Quality by Nanodrop
Quality  of  samples  was  checked  using  the  Nanodrop  ND-1000  (Ambion,  UK),  a 
spectrophotometer designed to analyse small amounts of RNA or DNA, by the following 
method. The Nanodrop was calibrated to zero using distilled water. 1µl of each sample was 
placed in the nanodrop machine and a photospectometry reading of RNA concentration 
and of A260/280 to assess purity was obtained. Quick assessment of nucleic acid purity 
is performed by determining the ratios of spectrophotometric absorbance of a sample at 
a	wavelength	of	260/280.This	procedure	was	first	described	by	Warburg	and	Christian	
as a means to measure protein purity in the presence of nucleic acid contamination, it is 
most commonly used today to assess purity of nucleic acid samples(95). For a summary of 
methods used in RNA extraction, see table two.
8.2.5.3 – Assessment of RNA Quality by Taqman PCR
In	conjunction	with	the	Ambion	method	of	RNA	extraction,	the	Real	Time	Taqman	PCR	
method was developed, to analyse samples for presence of GAPDH (internal house-
keeping gene) and NIS sequences. The methods used for analysis for both GAPDH and 
NIS	are	described:	47
8.2.5.3.1 – NIS
Briefly,	RT	was	performed	as	follows.	A	mastermix	was	made	up,	containing	80µl	of	5X	
RT mix, 40µl 0.1M DTT, 20µl 25mM deoxy Nucleotide Triphosphates (dNTPs), 20µl 
random hexamers and 20µl H20.
To this 180µl mastermix was added 20µl M-MLV and 10µl RNAse inhibitor. The RNA 
was heated to 65°C for 5 minutes, then centrifuged at a maximum speed and placed on 
ice. 21µl of the master mix was added to 19µl of RNA and incubated at room temperature 
for 10 minutes. Then samples were placed in an incubator at 37°C for 2 hours.
Following this step, samples were heated to 65°C in a heating block for 10 minutes and 
stored at -20°C.
Initially	NIS	specific	probe	and	primers	(TAGN,	Newcastle,	UK,	as	before)	were	used	
in	the	following	mastermix	(sufficient	for	10	reactions)	–	12.5µL	2X	Taqman	mastermix,	
0.125 µl of probe, 0.25µl of forward and reverse primers and 9.375µl of H20. 22.5 µl 
mastermix was added to 2.5µl cDNA within each well of a 96 well plate. Then, the plate 
was	briefly	centrifuged.
Thereafter the 96 well plate was loaded on the Taqman machine.
The plate was heated to 50°C for 2 min, 95°C for 10 min then 40 cycles of 95°C for 15 
sec, followed by 60°C for 1 min.
Samples were run in duplicate with nuclease-free H20 as a negative control in both RT and 
PCR steps, and NIS standards as a positive control.
Standards	were	made	up	as	follows:	RNA	was	extracted	from	NIS-6,	which	is	a	cell	line	
known to express NIS. cDNA was made by reverse transcription as described in section 
7.2.12. 400µl dsDNA was made from cDNA in a standard PCR reaction as described in 
section 7.2.1.2 using NIS primers.
10µl of double stranded DNA was run on a gel to check that NIS signal was detected. 48
The	NIS	cDNA	was	then	purified	using	the	Minelute	PCR	Purification	kit	as	follows.	The	
cDNA was placed in spin columns, and 400µl Buffer HC was added per 100µl dsDNA. 
The protocol was followed and 200µl eluted volume was obtained. The ds DNA was 
placed	in	a	photospectrometer.	The	concentration,	as	quantified	at	A260,	was	0.28	µg/µl.
The	following	equation	was	used:
No of molecules ds NIS per µl volume = A260/13.2 X S X Avogadro’s Number/10¹²,
Where S is size of NIS fragment (0.137) in base pairs.  
So, 0.28/ (13.2 x 0.137) X 6.02 x 10²³/10¹²
= 0.28/1.8084 X (6.02 x 10¹¹)
= 0.1548 X (6.02 x 10¹¹)
= 0.932  X 10¹¹
= 9.32 x 10¹°  molecules NIS /µL.
1/9.32 = 0.107, so 10.73µl double stranded DNA was added to 89.27µl H20 to make up 
100µl of 10¹° molecules /µl solution.
Serial dilutions were made from this solution in order to obtain standards containing 101 
to 108 copies of NIS-PCR product per reaction. 
8.2.5.3.2 – GAPDH
8.2.5.3.2.1 – One-step Method
In initial experiments at GRI laboratory, sample integrity was established by analysis of 
the expression of the housekeeping gene GAPDH using a one-step RT-PCR protocol, as 
was standard there. It was felt that a one-step process was less prone to error than two-
step processes, and should be used when initially attempting to analyse whether RNA had 
been	successfully	extracted	from	paraffin	embedded	tissue.		49
Briefly,	the	one-step	method	to	detect	GAPDH	only	was	as	follows:	GAPDH	signal	was	
detected using standard ABI (Applied Biosystems, Warrington, UK) primers and probe.   
For each GAPDH reaction, 0.625µl ABI Multiscribe, 1.25µl ABI Probe/Primers mix, 
12.5µl ABI Universal mix and 8.625µl nuclease- free H20 (Ambion) were added. 2µl of 
sample RNA was added to 23µl of this master mix.
Sample and mastermix were added to wells in a 96 well plate. Thereafter the 96-well 
plate	was	loaded	on	the	Taqman	machine.	PCR	conditions	were	as	follows:	48°C	for	30	
minutes, 95°C for 10 minutes, then forty cycles of 95°C for 15 seconds followed by 60°C 
for 1 minute. 
8.2.5.3.2.2 – Two-step Method
As good quality RNA was not reliably detected using the one-step method, a more familiar 
two-step method, as used in analysing RNA extracted from cell lines was used. It was felt 
it may be easier to determine problems with the NIS reaction, if the steps were separated. 
two-step Taqman RT-PCR allowed exact quantitation of starting number of copies of each 
target sequence under identical reaction conditions. Initial copy number was established 
using a standard curve.
Briefly,	RT	was	performed	as	follows.	A	mastermix	was	made	up	(sufficient	for	10	
reactions), containing 80µl of 5X RT mix, 40µl 0.1M DTT, 20µl 25mM deoxy Nucleotide 
Triphosphates (dNTPs), 20µl random hexamers and 20µl H20.
To this 180µl mastermix was added 20µl M-MLV and 10µl RNAse inhibitor. The RNA 
was heated to 65°C for 5 minutes, then centrifuged at a pulse spin and placed on ice. 21µl 
of the master mix was added to 19µl of RNA and incubated at room temperature for 10 
minutes. Then samples were placed in an incubator at 37°C for 2 hours.50
Following this step, samples were heated to 65°C in a heating block for 10 minutes and 
stored at -20°C.
Taqman	PCR	step	was	then	performed	as	follows:		A	mastermix	was	made	up	using	2x	
Mastermix (ABI) – 12.5µl per sample, Probe/primer mix (ABI) – 1.25µL per sample 
and Nuclease free H20 - 8.75µl per sample. 22.5 µl mastermix was added to 2.5µl cDNA 
within	each	well	of	a	96	well	plate.	Then,	the	plate	was	briefly	centrifuged.
Thereafter the 96 well plate was loaded on the Taqman machine.
The plate was heated to 50°C for 2 min, 95°C for 10 min then 40 cycles of 95°C for 15 
sec, followed by 60°C for 1 min.
Samples were run in duplicate. 
ABI 7700 sequence detection software determined the initial amounts of target sequence 
present in samples by direct comparison of their Threshold cycle (Ct) value with the Ct 
values of known standards (see section 10.2.2.1.1 for explanation of Ct value), which 
were used as positive controls. Nuclease- free H20 was used as a negative control in both 
RT and PCR steps. GAPDH Standards were made up as described in NIS section 8.2.6.1. 
RNA was extracted as described from NIS-6 cell line. The size of GAPDH product was 
432 base pairs. 51
Section 9 – Radioisotope Imaging
9.1 – Materials
9.1.1 – General Equipment
A	whole	body	gamma	camera	scanner	(Philips	Prism	2000XP)	fitted	with	a	low	energy	
general purpose collimator was employed and a 15% window, centred on the 140keV 
photopeak, was selected to image whole body distribution.
Tc99m Pertechnetate was obtained from the radiopharmaceutical department on site at 
the	Western	Infirmary,	Glasgow.
9.2 – Methods
An ideal radioisotope has a half life similar to the length of the test, and is available at the 
site of the test. As outlined before, Tc99m Pertechnetate has these qualities and is relatively 
cheap. It is widely used in nuclear medicine departments already, in bone scanning 
protocols. It is generated on site from decay of its parent compound molybdenum-99. 
Tc99m Pertechnetate decays by electron capture and emits gamma rays with an energy 
of 140 keV.
Imaging of the distribution of a radioisotope is by a gamma camera. This consists of 
a large detector in front of which the patient is positioned. This camera is computer 
controlled, to allow variation in scan acquisition time, and from which copy images can 
be generated. Gamma rays are emitted in all directions and require to be “focused” via 
a collimator. Following this the gamma camera acquires an image of the radioisotope’s 
distribution, by detection of the collimated gamma rays emitted by the radioisotope, which 
are	transformed	into	flashes	of	light	by	the	scintillation	crystal.	This	light	is	then	converted	
into electronic signals by photomultiplier tubes. These signals contain information on the 
spatial localisation of the source of the emitted gamma rays, and their magnitude.
A  low  energy  collimator  was  used,  in  order  to  obtain  the  best  imaging  of  Tc99m 
Pertechnetate decay. Maximal image resolution was achieved by placing the collimator 
close to the organ of interest.52
Patients were recruited from the Beatson oncology centre metastatic breast cancer clinic. 
They were screened for eligibility by reading of the case notes. If agreeable to receiving 
information  in  the  study,  they  were  given  a  consent  form  and  counselled.  Standard 
inclusion	and	exclusion	criteria	applied	(see	figures	four	and	five).
A protocol amendment was made, with 2 changes to the original Study Protocol.
These	were	as	follows:
1) An amendment to the length of time prior to radio-isotope imaging in which screening 
procedures can take place.
2) An amendment to allow patients on regular bisphosphonates to be recruited into this 
study.
The	 rationale	 for	 this	 was	 as	 follows:	 patients	 who	 are	 currently	 recruited	 into	 this	  
study	 are	 seen	 at	 breast	 clinics	 and	 their	 eligibility	 confirmed.	 However,	 because	
of  waiting  times  in  the  nuclear  medicine  imaging  department,  scans  are  often  not 
performed  within  14  days.  Consequently  patients  will  require  a  further  visit  for  a   
repeat	blood	profile	adding	to	an	unnecessary	visit	for	the	patient.	As	these	patients	  
are	not	on	any	specific	anti	cancer	therapy	it	is	not	expected	there	be	any	change	in	either	
their blood screen or their clinical condition between screening and the imaging and the 
plan	is	therefore	to	allow	more	flexibility	in	the	time	from	screening	investigations	up	to	
28 days.
Increasingly  patients  with  advanced  disease,  who  are  the  target  population  for  this 
study, are on bisphosphonates. It is not anticipated that bisphosphonates would change 
the expression of the NIS gene, while theoretically this may be the case for hormonal 
therapy. The exclusion criteria where therefore changed to allow patients who are on 
regular bisphosphonates but no other therapy to be recruited into this study.
The	eligibility	criteria	were	later	modified	during	the	study	to	allow	patients	who	were	53
receiving chemotherapy to be included in the study. Other published studies had not 
excluded patients on the basis of any treatment, and there was felt to be no convincing 
evidence that chemotherapy should interact with NIS expression.
All patients were scanned according to the protocol which had been agreed upon by 
the	investigators	prior	to	commencement	of	the	first	phase	of	the	study.	This	was	as	
follows:	Imaging	was	undertaken	at	4	hours	and	24	hours	after	intravenous	administration	
of	600MBq	Tc99m	Pertechnetate.	At	4	hours	after	injection,	a	scanning	whole	body	
acquisition was performed for 20 minutes duration into a 256 x 1024 matrix.  Additional 
static images of the axilla were acquired into a 512 x 512 matrix for 400s duration.  A 
further	whole	body	scan	was	acquired	24	hours	after	injection	for	a	total	scanning	time	
of 45 minutes.
There were three phases of the study in total. In phase one, the scanning protocol involved 
intravenous	injection	of	600MBq	of	Tc99m	Pertechnetate	with	no	blocking	agent.
In phase two of the study perchlorate, a blocking agent, was administered intravenously 
at the same time as the Tc99m Pertechnetate. The aim of this agent was to decrease 
endogenous uptake as per published evidence(96).
In the third phase of the study, blocking of endogenous uptake was attempted via use 
of potassium iodate – 170mg potassium iodate was given orally 30 minutes before the 
Tc99m Pertechnetate. This is a well recognised agent used to block thyroid uptake in 
nuclear incidents, and also clinically(97)(98). 
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Section 10 – Results
10.1 – Pathology Details
Thirty-three patients in total were recruited into the clinical study, and gave consent for 
their tissue to be obtained and to be scanned. The median age of the patients in the study 
was 57 years old. The median time which had elapsed since the original breast cancer 
diagnosis in those patients scanned was 4.4 years. Patients who were recruited into the 
study had a range of metastatic disease which included bone, visceral, soft tissue and 
nodal disease, and a combination of these. Sites of metastatic disease in the patients who 
underwent radio-isotope imaging for NIS uptake are shown in table six. One patient 
(patient 11) had two breast primaries treated simultaneously. In this case pathology blocks 
were obtained from the left breast only, as this was most clinically relevant.
Tumour tissue blocks were only requested for the 24 patients who ultimately entered the 
NIS imaging trial. Nine patients withdrew consent for the scanning trial. Reasons for 
withdrawal were not pursued, but in general patients felt unwilling or unable to attend. 
No sample was received from patient nine. 
The total number of patients whose tissue samples were obtained for NIS expression 
studies was 23. ER status was available for 22 of these 24 patients. Twelve patients in 
the study were oestrogen receptor (ER) positive, 10 were ER negative. In all cases where 
results were available, ER status was assessed by IHC.
With	regard	to	Her-2	status,	five	patient	samples	were	positive	by	IHC	(1	was	1+,	4	
were 3+), and 12 were negative. Results were unavailable in seven patients. Progesterone 
receptor status (PR) was available in 10 patients, and was positive in four, negative in six. 
Grade was available in 15 cases, and was Grade 1 in one patient, Grade 2 in four patients, 
and Grade 3 in 10 patients.  
Pathological	type	was	available	in	21	patients	and	was	ductal	in	the	majority	–	18	–	
and lobular in three. Pathological type was unavailable for three patients, in one case 
as records of reports were not held back as far as 1995, in one patient who had a core 55
biopsy only, and in one where only nodes and lymphatics were involved, with no obvious 
primary tumour to allow further analysis.
Fifteen patients were node positive (10 patients were TNM stage N1, two were N2 and 
three were N3).
Of the 15 patients who were NIS positive by IHC, ER results were available in 14. Seven 
patients were ER positive according to pathology records (50%). Of these seven patients, 
four demonstrated Tc99m Pertechnetate uptake (57%).
Of	those	11	patients	who	demonstrated	positive	uptake	on	scintigraphy,	five	were	ER	
positive also. Only one patient with positive scintigraphy was Her 2 positive, however 
this was only analysed in six of these cases.
For pathological information on the study patients, please see table nine.
It should be noted that these results were obtained from patient’s pathology records.
For details of current therapy of the patients who were scanned in this study please see 
table 10. Three patients were about to start chemotherapy, but had no previous exposure 
to	treatment	for	metastatic	disease.	One	patient	was	receiving	neoadjuvant	chemotherapy	
for	non-metastatic	disease.	Twenty	patients	were	receiving	between	their	first	and	seventh	
line of treatment for metastatic disease. Six patients were either receiving or had completed 
first-line	treatment	for	metastatic	disease,	three	were	on	second-line	treatment,	five	on	
third	line,	one	patient	was	on	fourth-	line	therapy,	one	on	fifth-line,	two	on	sixth-line	and	
two on seventh-line treatment.  56
10.2 – Immunohistochemistry 
Immunohistochemistry is scored by assessing the number of cells which stain for the 
protein in question, and the intensity of this staining, usually graded 0-3. The Histoscore 
has been developed, particularly in breast cancer, as a single measure of positivity, attained 
by combining these two parameters, to a maximum score of 300(99).
See	figures	six	to	eight	for	examples	of	immunostaining	that	can	be	seen	with	NIS	in	
malignant breast and thyroid tissue, and Graves’s thyroid tissue. See table three for a 
summary of immunocytochemical methods used by other groups, who have looked at 
NIS IHC expression.
In this study, 4µm sections of thyroid tissue, both malignant and Graves’s disease, were cut 
using a microtome and mounted on glass slides. All parameters described in Section 6.2 
were	optimised:	Antigen	retrieval	methods	(EDTA	and	citrate),	varying	concentrations	of	
antibody dilution, manual and DAKO automated staining. Optimisation was performed 
by comparison of thyroid positive control tissue using all these different methods, by 
examination  under  the  microscope.  In  addition  both  the  rabbit  anti-NIS  polyclonal 
antibody, which was a kind gift from Professor Jhiang, and the monoclonal antibody 
(Chemicon, MAB3564) were compared. 
Using the polyclonal rabbit anti-NIS antibody with EDTA antigen retrieval, staining with 
one in 1000 dilution, for 60 minutes using the DAKO Autostainer demonstrated the most 
consistently strong staining of thyroid Graves control slides.
Malignant tissue removed at the time of original surgery or diagnosis was available for 
analysis in 22 of the study patients (patients 1-8, 10-12, 14-23 and patient X). The tissue 
had	been	stored	at	room	temperature,	and	paraffin	embedded.		The	sample	from	patient	
13 was a core biopsy only and too degraded to be informative at immunohistochemistry. 
The sample from patient nine was never received from the pathology department and 
therefore there is no IHC for this patient. 
Patient X, had IHC performed on her pathology sample, but withdrew consent to be 57
scanned.
In two patients (patients 15 and 17), nodal and/or lymphatic tissue was assessed only, 
rather than the breast tissue, as this was the sample which when assessed on standard 
Haematoxylin and Eosin (H and E) staining was felt to be least degraded, and therefore 
most likely to be informative. In patient 15, nodal and lymphatic tissues were assessed, 
and	in	patient	17,	a	jugular	node	was	assessed.				
For each breast tissue sample, 2 x 4µ sections were cut using a microtome and mounted 
on glass slides, one with no primary antibody as a negative control. Graves thyroid tissue 
was used as a positive control in every case. 
Therefore 22 breast cancer tissue samples were evaluable for NIS expression by IHC 
(please see table four).
Staining intensity was graded visually, from 0-3 + by 2 observers, with 3+ being represented 
by the positive control of a Graves disease sample. 
The number of cells was assessed using a semiquantitative scoring method that evaluates 
the number of positive tumour cells over total tumour cells, ie the percentage of positive 
tumour cells. This method, as compared to a categorical scoring system (eg simply 
classed  as  positive  if,  for  example  >10%  positive),  showed  substantial  agreement 
between observers (100). Interobserver agreement between the two observers in this study 
was excellent, with agreement on intensity of staining in all cases, with a third observer 
scoring a proportion of samples and who was in agreement.  Percentage of cells which 
were staining was agreed within 10% in all cases.
No samples showed 0 grade staining. A typical example of NIS protein expression in a 
Graves thyroid control as demonstrated by 3+ staining by IHC is shown for reference (see 
figure	nine).	Staining	was	not	as	intense	in	differentiated	thyroid	cancer,	an	example	of	
which	is	seen	in	figure	10.
NIS protein expression was detected in all 22 cancer samples. In patient 15, two samples 58
were analysed -a4 which was nodal tissue, and a7 which was lymphatic tissue. In both 
of these cases 100% of cells demonstrated staining, but in a4 the intensity was described 
as 2+ and in a7 as 3+. Therefore both samples demonstrated positive IHC, albeit with 
slightly different Histoscores (200 and 300).
In the other 21 patient samples, 3+ staining occurred in two samples, 2+ in 11 samples, 
and 1+ in eight samples.
A mean of 85 % of cells stained, with a range of 20-100%, and a median of 80%. The 
mean Histoscore was 154, with a range from 20-300, and a median value of 160.
Cytoplasmic	NIS	protein	expression,	as	defined	by	IHC,	was	detected	in	all	22	breast	
cancer tissue samples, in four of which membranous NIS staining was also observed. 
Of these, two of four demonstrated positive staining in 100% of cells, and two of four 
demonstrated positive staining in 80% of cells.
Fifteen	cases	were	defined	as	truly	immunopositive,	with	the	criteria	for	true	positivity	
being a Histoscore of > 150, or demonstration of membrane staining. Seven cases were 
negative	by	the	above	criteria.	See	table	four	for	immunocytochemistry	results,	and	figures	
11 and 12 for examples of immunostaining from study patients.
In addition, breast cancer tissue removed at the time of original surgery was available 
for analysis in 25 patients who were randomly selected from the pathology department 
archive. These samples were analysed by immunocytochemistry using the Chemicon anti-
NIS monoclonal antibody as described above in section 6.2. Reaction conditions were 
optimised using differentiated thyroid cancer blocks as a positive control, as described 
in section 6.2. These showed consistently poor staining, with no sample demonstrating 
membranous staining or scored as having cytoplasmic staining >20%.
Eleven blocks were randomly selected from these 25 samples and re-analysed with the 
polyclonal anti-NIS antibody from Professor Jhiang, when this became available. Due 
to time constraints, all of the randomly selected samples could not be re-analysed. None 59
of 11 blocks demonstrated positive immunostaining, as assessed by the afore-mentioned 
criteria	(see	table	five).	The	mean	percentage	of	cells	staining	was	32%,	with	a	median	of	
30. The mean Histoscore was 38%, with a median of 30%. 
Of note, in this study, samples were analysed independently by two observers, with a third 
observer reviewing a proportion of samples, ensuring reliability of results.
10.3 – RNA Extraction and Analysis of NIS RNA Expression 
Most	archival	tissue	in	pathology	departments	is	formalin	fixed	and	paraffin	embedded.	
Whilst DNA can be extracted reliably, these samples are challenging in terms of RNA 
extraction, as there is a great propensity for extensive RNA degradation before completion 
of	the	formalin	fixation	process.	In	addition,	formalin	fixation	can	cause	cross-linkage 
between nucleic acids and proteins and can also covalently modify RNA by the addition 
of  mono-methylol  groups  to  the  bases,  making subsequent  RNA  extraction,  reverse 
transcription and quantitation analysis problematic (101).
Traditionally, RNA extraction techniques have involved the use of hazardous organic 
solvents	in	the	guanidinium	thiocyanate	method	to	remove	paraffin	and	purify	nucleic	acids.	
Several researchers have demonstrated that RNA extraction can be achieved reliably from 
formalin-fixed	paraffin-embedded	tissue,	using	traditional	acid	guanidinium	thiocyanate-
phenol techniques(102)(103). These methods are time consuming, however and a number 
of	column	based	kits	have	been	developed.	Generally,	FFPE	samples	are	deparaffinated	
using	a	series	of	xylene	and	ethanol	washes.	Following	this,	samples	are	subjected	to	a	
protease digestion step with an incubation time tailored for recovery of RNA. The nucleic 
acids	are	purified	using	a	rapid	glass-filter	methodology	that	includes	an	on-filter	nuclease	
treatment and are eluted into either water or the low salt buffer provided. In addition, 
newer methods of extracting RNA have been developed, for example with the use of 
laser capture microdissection(104). This is a method which allows for isolation of pure cell 
populations from histologic sections. 60
When analysing potentially degraded tissue, which is likely to contain small fragments 
of RNA, an approach utilizing quantitative PCR (Taqman PCR) seems to be particularly 
suitable, as it allows for quantitative determination of gene transcript levels even in tissue 
extracts containing partially fragmented RNA. As this experimental strategy requires only 
minute amounts of RNA it should be applicable to	formalin-fixed,	paraffin-embedded	
tissue sections. Furthermore, the ability of Taqman PCR to assay very small fragments of 
mRNAs makes this technique amenable to studies where the RNA is moderately or even 
highly degraded, as in the case of RNA from archived tissues(105).
10.3.1 – RNA Extraction and Analysis of NIS Expression from Cell Lines In Vitro
RNA was extracted from the cell lines UVW-NIS, MCF7, and T47D, using the Qiagen 
RNeasy kit as described in section 7.2.1. RT-PCR to isolate NIS RNA was performed 
as described previously in section 7.2.1 2. Gel electrophoresis of the PCR products 
demonstrated that UVW-NIS was positive for NIS gene expression. However, neither 
T47D	nor	MCF7	expressed	NIS	in	detectable	amounts	(see	figure	13).
10.3.2 – RNA Extraction and Analysis of NIS Expression from Paraffin Embedded 
Tissue
With the methods described in Section 8, consistently good signals were obtained with 
the GAPDH reactions, but very little signal was detected from the NIS reaction. It was 
considered possible that NIS primers and/or probe may have degraded with time and/or 
exposure to light. Therefore, in an attempt to optimise the reaction, new NIS forward and 
reverse primers and probe were designed and obtained from ABI. These had the same 
sequence as described in section 7.2.1.2, corresponding to a 137 base pairs amplicon. 
These were supplied as a pellet and required to be reconstituted. This was performed using 
1Mm Tris-hydrochloride ph 8 / 0.01Mm EDTA, to a 100µM working concentration.
Initially, reactions were performed as in section 8.2.6.1, using 0.25µl probe and primers 
in a 25µl reaction volume (ie 10µM). The method was optimized using 5µM and 20µM 
probe concentration. Improved results were seen with 5µM. A further attempt was made 
to optimise results by using 45 PCR cycles. However, best results for NIS were seen using 61
5µM probe concentration, 10µM primer concentration and 40 PCR cycles (see appendix 
1, slide 1).
Tissue blocks were requested for 24 patients. In four cases (patients nine, 22, 23 and 24) 
samples could not be obtained, or were not analysed due to time constraints. Of note, RNA 
was extracted and analysed from the core biopsy for patient 13, as there was adequate 
tissue, but there was not adequate tissue to perform IHC. The sample was run for IHC, 
but on review was felt to be too poor to analyse in terms of quality. Therefore 20 samples 
were available for analysis for RNA extraction and RT-PCR to analyse NIS expression.
Extensive	attempts	were	made	to	extract	RNA	from	formalin	fixed	paraffin	embedded	
tissue (FFPE) using a number of kits. Details are found in section 8.2.3.
Briefly,	when	the	Qiagen	kit,	which	had	been	used	successfully	to	extract	RNA	from	cell	
lines as described previously, was used, no bands were seen consistently on agarose gel 
electrophoresis,	suggesting	no	good	quality	RNA	had	been	obtained	(see	figure	14).
Thereafter, similar attempts with the ZYMO kit, suggested that the quality of the RNA 
was poor. 
The Trizol method, which is established for extracting RNA from fresh tissue at GRI 
pathology department was then used, again with similar results. RNA quality was analysed 
by agarose gel electrophoresis, and revealed no good quality RNA.
The Purescript kit revealed little RNA as assessed by detection of GAPDH by Taqman 
PCR. The Ambion  kit  consistently  revealed  good  RNA  as  assessed  by  detection  of 
GAPDH by Taqman PCR.
10.3.2.1 – Assessment of RNA quality
Nanodrop and Taqman PCR were used to analyse RNA quality.
10.3.2.1.1 – Assessment of RNA quality by Nanodrop
Samples were assessed using the Nanodrop machine as described in section 8.2.5.2.62
Results were not available for patient nine, but all other results are presented in table one, 
and	purity	was	good	in	the	majority	of	samples,	as	was	concentration.	
10.3.2.1.2 – Assessment of RNA Quality by Taqman PCR
Real-time	PCR	is	a	method	that	determines	the	presence	of	a	specific	DNA	sequence.	A	
fluorescent	reporter	is	released	during	the	amplification	cycle.	This	reporter	is	covalently	
linked	to	the	5’end	of	a	probe	specific	to	the	sequence	of	interest,	and	a	fluorescent	
quencher is linked to the 3’ end. When the probe is intact, the proximity of the reporter to 
the	quencher	suppresses	reporter	fluorescence.
During PCR, the probe anneals to the target sequence, and the polymerase has activity 
which	cleaves	the	probe.	The	increase	in	fluorescence	from	the	reporter	is	quantified.	
Quantification	is	performed	by	assessing	the	Threshold	cycle	(Ct),	which	is	the	point	
where the PCR reaction enters the exponential phase, and the total amount of free reporter 
rises above the background level. The quantity for each sample is derived from the Ct 
value.  The machine compares the Ct value for every sample to the Ct values from the 
standards for the target sequence in question eg NIS or GAPDH. As samples are run in 
duplicate, the machine calculates the mean quantity.
RNA extraction using the Ambion method was performed as described in section 8.2.3.5. 
The RT step was performed as described in section 8.2.3.5. RNA was extracted from 
the 20 available study patient breast cancer samples reliably using the Ambion kit, and 
analysed using the Taqman 7900HT machine, as per the described protocol in section 
8.2.6.	To	confirm	RNA	was	of	good	quality,	it	was	analysed	by	the	Nanodrop	as	described	
in section 8.2.5.2 (see table one). Taqman PCR was performed as described in section 
8.2.6. The housekeeping gene GAPDH was consistently detected in patient samples. (See 
table seven). All samples were run in duplicate.
Threshold cycle (Ct) numbers for the GAP reaction were between 24 and 39. Mean 
quantity varied between 3130 and 4.67 x 107.
NIS	was	detected	only	in	the	Graves	thyroid	RNA	and	paraffin	embedded	NIS	expressing	63
cells (see table seven for results and appendix one for examples). NIS was not detected 
by this method in the breast tumour samples. 
10.4 – Radioisotope Imaging
Patients were recruited from the Beatson oncology centre metastatic breast cancer clinic, 
as described in section 9.2.1. In all patients who underwent scintigraphy, the nuclear 
medicine scan was correlated with standard imaging. The timescale of imaging and 
imaging modality are summarized in table six. Computed tomography (CT), bone scan 
and chest x-ray (cxr) were all used as well recognized standard staging investigations.     
10.4.1 – Phase One
Ten patients were recruited and eight patients were scanned in this phase of the study. Two 
patients declined to be scanned. The protocol as described in section 9.2.1 was adhered 
to in all cases. One additional patient who was recruited into the second phase will be 
included as she was mistakenly given no blocking agent (patient 18).
Of	the	nine	patients	in	total	(numbers	one	to	eight,	and	18),	a	mixture	of	findings	were	
demonstrated on conventional imaging. Please see table six for details. In summary, 
patients one, four  and 18 demonstrated visceral, bone and nodal metastases on conventional 
imaging,	patients	two,	three	and	six	had	visceral	and	bone	metastases,	patients	five	and	
seven had visceral and soft tissue disease, and patient eight visceral and nodal disease.   
All	images	were	reviewed	by	a	panel	of	five	investigators	(myself,	Professor	of	Nuclear	
Medicine,	Consultant	Medical	Oncologist,	Scientific	group	leader,	and	nuclear	medicine	
scientist) with the investigators “blinded” for the clinical details, and corresponding 
conventional	imaging	findings,	and	a	consensus	reached	on	the	NIS	scan	findings.	Positive	
uptake of Tc99m Pertechnetate was observed in two patients (patient numbers three and 
six) in both cases in bone metastases. Both of these patients had known visceral and bone 
disease but only demonstrated bony uptake, i.e., differential uptake was seen at different 
disease sites. Patient three demonstrated uptake only in the pelvis, lumbar spine and left 
shoulder, whereas on conventional imaging had shown disease in almost whole skeleton 64
including skull base, spine, pelvis, rib cage, shoulders, humeri and femora  (isotope 
bone scan), and liver and  lung on liver Ultrasound scan(Uss) and chest x-ray (cxr). It 
should be noted that conventional imaging had been performed three to four months 
before the Tc99m Pertechnetate scan, and the patient had been receiving treatment with 
a bisphophonate, perhaps altering the activity of her bone disease. She had also recently 
completed treatment with FEC chemotherapy, perhaps altering uptake in visceral lesions, 
although a cxr during chemotherapy showed responding but present lung metastases, and 
a liver Uss showed worsening liver metastases.  
In patient six, uptake was seen in only the left femoral head and mediastinum, thought to 
be either left pleural disease or a thoracic spine lesion by the panel. No uptake was seen 
in T4 or L3 vertebrae, or right pleural effusion, pericardial effusion or small lung nodules 
(see	appendix	two,	figures	one	and	two).	This	patient	had	a	seven-month	gap	between	
conventional and study imaging, and had again been receiving regular bisphosphonate. 
The lung nodules on CT were not absolutely diagnostic of metastases, and should be 
viewed as inconclusive.    
Marked  physiological  uptake  was  seen  in  this  phase  of  the  study  which  impeded 
interpretation of images. This was most marked in the stomach, salivary glands and thyroid 
gland	at	4	hours,	and	in	the	bowel	at	24	hours	(see	appendix	two,	figures	three	and	four).	
Some	improvement	followed	software	masking	of	images	(see	appendix	two,	figure	five).	
This involved masking of sites of physiological uptake of Tc99m Pertechnetate, using 
Link Medical MAPS 10000 software.  Regions of interest were drawn manually around 
sites	of	physiological	uptake	on	images	in	the	anterior	and	posterior	projections.		Counts	
within these regions of interest were then set to zero.
Of note, the 20-minute image did not provide any additional information to the 4-hour 
image.65
10.4.2 – Phase Two
Twelve patients were recruited into this phase of the study and 10 were scanned. Two 
patients withdrew consent to participate in the scanning study. 
As stated previously, one patient did not receive perchlorate so has been included for 
analysis on phase one. One patient from phase three received perchlorate, rather than 
potassium iodate and will be included in this phase. Other than this, the agreed protocol 
as	described	in	section	9.2.1	was	followed.	Briefly,	in	this	phase,	an	attempt	was	made	to	
block physiological uptake with escalating doses of perchlorate. Doses of 100 to 300 mg 
were	administered,	with	two	patients	receiving	100mg,	three	receiving	200mg,	and	five	
receiving 300mg perchlorate.
In  terms  of  conventional  imaging,  the  ten  patient’s  characteristics  were  as  follows 
(numbers	9-17	and	23):	two	patients	had	bone	only	disease,	two	had	nodal	disease,	three	
had a combination of visceral and bone disease, one had breast and nodal disease, one had 
visceral and nodal disease, and one had visceral and soft tissue disease.
All	images	were	reviewed	by	a	panel	of	five	investigators	(myself,	Professor	of	Nuclear	
Medicine,	Consultant	Medical	Oncologist,	Scientific	group	leader,	and	nuclear	medicine	
scientist) with the investigators “blinded” for the clinical details, and corresponding 
conventional	imaging	findings,	and	a	consensus	reached	on	the	NIS	scan	findings.	Five	
patients demonstrated positive uptake (10, 13, 14, 16 and 23). Patient 10 had received 
100mg, patient 13 had received 200mg, and patients 14, 16 and 23 had received 300 mg 
of perchlorate. Patient 10 revealed Tc99m Pertechnetate uptake in only one site of disease 
– supraclavicular nodes, which was the only disease noted on conventional imaging, 
i.e., she had uptake in all her known metastatic disease. Patient 13 was known from 
conventional imaging (CT) to have a large breast primary, and also small axillary nodes. 
These	were	also	palpable	clinically.	She	went	on	to	have	neoadjuvant	chemotherapy,	and	
at the time of mastectomy and axillary node clearance, was found to have had a complete 
pathological response, with no evidence of malignancy in her breast or axillary nodes (10 66
removed). Therefore, the axillary nodes seen on CT, but not on the Tc99m Pertechnetate 
scan may have been reactive only.
Patient 14 was seen on CT to have multiple bilateral lung metastases, and a large chest 
wall mass. Uptake with Tc99m Pertechnetate was seen only in the large chest wall mass, 
not the small lung metastases. However, this may have been related to size as these 
metastases were subcentimetre in size. 
Patient 16 had disease on conventional imaging in liver, bone and a pleural effusion. 
Tc99m Pertechnetate uptake was demonstrated in the pleural effusion only. 
Patient 23 had MRI and CT performed which revealed small bowel disease (this was 
biopsy proven), and whole vertebral column disease on MRI. Her imaging had not been 
updated during her six cycles of FEC chemotherapy, as MRI spine was static over a 
period of years, and CT was not felt to be helpful. This was the reason that there was a 
long interval between her conventional imaging and Tc99m Pertechnetate scan. However, 
this patient did have a CT at the end of her course of chemotherapy, which was one month 
after her Tc99m Pertechnetate scan, and this suggested peritoneal disease, and possible 
porta	hepatis	nodes.	Of	note,	later	CT	imaging	did	not	confirm	findings	of	nodes	at	porta	
hepatis,	and	therefore	this	was	not	likely	to	be	of	significance.	Also	of	interest,	this	patient	
had vertebral disease seen repeatedly on MRI, but isotope bone scanning was normal. 
Tc99m Pertechnetate uptake was seen only in the vertebral column, and not convincingly 
in	the	small	bowel.	However,	this	is	a	difficult	area	to	visualise	on	Tc99m	Pertechnetate	
scanning due to general physiological uptake, which was seen despite administration of 
300mg perchlorate.      
Therefore,	of	the	five	patients	who	demonstrated	uptake	on	Tc99m	Pertechnetate	scanning,	
differential uptake was seen in at least four of these, with only one patient showing uptake 
in all the known sites of soft tissue disease, although there was only one site of known 
disease within this patient (patient 10). It should be noted that patient 13 may have only 
had actual malignancy in her breast lesion and not in the axillary nodes seen on CT.67
One patient demonstrated uptake in only their known soft tissue lesion (patient 14), and 
one patient in only one of two sites of visceral disease and not at all in bone metastases 
(patient 16). One patient with disease in spine and small bowel mesentery demonstrated 
uptake in spine only (patient 23). 
For	 Tc99m	 Pertechnetate	 images	 of	 these	 patients	 please	 see	 appendix	 two,	 figures	  
six to 10.
Perchlorate appeared to qualitatively reduce physiological uptake most markedly in the 
bowel, with no obvious response to increasing dose from 100mg to 300mg. A temporal 
effect was noted between the 4 hour and 24 hour scans, i.e. a difference in intensity of 
uptake was seen at these two different time points, in some cases with blocking seeming 
to be impaired at 24 hours. For example, in patient 16, thyroid activity seemed to be 
evident at 24 hours, and not seen at 4 hours, indicating that thyroid uptake was blocked at 
least	initially	(see	appendix	two,	figure	11).
10.4.3 – Phase Three
Ten patients were recruited, and six were scanned. Four patients withdrew consent for the 
scanning study.
One patient with disease in the spine and in the small bowel mesentery demonstrated 
uptake in the spine only (patient 23). This patient received 300 mg perchlorate, and 
therefore will be included in phase two for analysis.
Five patients were therefore analysed (numbers 19-22 and 24).
In	terms	of	conventional	imaging,	the	five	patient’s	characteristics	were	as	follows:	one	
patient had disease in soft tissue only, one in nodal areas only, one in viscera and bone, 
and two had visceral, bone and nodal disease.
All	images	were	reviewed	by	a	panel	of	five	investigators	(myself,	Professor	of	Nuclear	
Medicine,	Consultant	Medical	Oncologist,	Scientific	group	leader,	and	nuclear	medicine	
scientist) with the investigators “blinded” for the clinical details, and corresponding 68
conventional	imaging	findings,	and	a	consensus	reached	on	the	NIS	scan	findings.	Four	
patients demonstrated positive uptake. One patient demonstrated uptake in her only site 
of disease which was a soft tissue mass (patient 19). Patient 20 demonstrated uptake in a 
sternal lesion only, with no uptake in liver, pleural effusion or rib and spine metastases. It 
should be noted that the pleural effusion was pleurodesed three years previously, which 
may have rendered it sterile.
One patient with extensive bone, nodal and liver metastases demonstrated uptake in the 
large liver lesion and lower vertebral metastases only (patient 22).  
One patient with disease in neck and axillary nodes showed uptake in neck nodes only 
(patient 24). However, it should be noted that the neck nodes (right supraclavicular) were 
noted clinically 18 months prior to the Tc99m Pertechnetate scan, and these and axillary 
nodes	were	confirmed	on	CT	at	that	time.	In	the	interim,	the	patient	received	two	lines	
of chemotherapy, with some response in the neck node and 6 months prior to the Tc99m 
Pertechnetate scan the patient received palliative radiotherapy to this area. The CT closest 
in time to the Tc99m Pertechnetate scan (three months prior) revealed new right axillary 
nodes, but right supraclavicular nodes were not seen. The Tc99m Pertechnetate scan 
detected uptake in the right supraclavicular area only, suggesting continuing activity in 
this area.
Please	see	appendix	two,	figures	12	to	15.
Potassium iodate 170mg was used as an agent to block physiologic uptake in this phase 
of	the	study.	In	three	of	the	five	patients	who	received	potassium	iodate,	there	was	no	
discernable thyroid uptake i.e., blocking was complete. In patients 20 and 24, however, 
there seemed to be incomplete blocking of thyroid activity i.e., minimal thyroid uptake 
was	seen	(see	appendix	two,	figure	16	for	example).	Please	see	table	eight	for	details.	
In summary, radio-isotope uptake was observed in 11 of 24 patients in total i.e., 46%. 
It should be noted that assessment of uptake was made in a qualitative, rather than 
quantitative manner.69
It was noted that two patients controlled on Thyroxine therapy (patients 11 and 15) showed 
no change in thyroid uptake, as compared with those not on Thyroxine. 
10.5 – Correlation Between Positive Scans and Positive IHC
Twenty-four patients were scanned in the imaging study. In two cases (patients nine and 
24), the breast cancer tumour samples were not obtained, as they could not be found in the 
relevant hospital archives. In one case (patient 13), the sample was too degraded to allow 
informative analysis. Of note, with respect to these three cases for which tumour samples 
were unavailable, one patient (patient nine) demonstrated no uptake on scintigraphy, and 
two (patients 13 and 24) showed Tc99m Pertechnetate uptake.
In one case, the patient had immunostaining performed on their breast cancer sample, but 
declined to be scanned due to ill health (patient X –see table four).  
Therefore, there were 21 patients with informative breast cancer samples in which NIS 
expression by IHC was performed and who underwent Tc99m Pertechnetate imaging. 
Comments  can  be  made  regarding  the  correlation  of  NIS  expression  by  IHC  and 
scintigraphy in these 21 patients only.
Positive	predictive	value	is	defined	as	the	number	of	true	positives/number	of	true	positives	
and	false	positives.	Negative	predictive	value	is	defined	as	the	number	of	true	negatives/	
number of true and false negatives.
Of the 14 patients (this excluding patient X) with positive expression of NIS in their 
breast cancer tissue sample, as measured by immunohistochemistry, eight patients (57%) 
demonstrated uptake of Tc99m Pertechnetate on scintigraphy i.e., were true positives, 
six did not, i.e., their screening test (IHC) had incorrectly predicted positive uptake on 
subsequent scanning (false positive screening). Therefore a positive predictive value of 
57% was observed when using immunocytochemistry as a screening test for detecting 
those patients who would go on to have a positive scan. In contrast, six patients had 
negative NIS expression by IHC, and no uptake on scintigraphy, i.e., true negatives. Only 
one patient had a false negative screening IHC result (patient 14). A negative predictive 70
value of 86% was seen when using immunocytochemistry as a screening test for detecting 
those patients who would have a negative scan.
Sensitivity	is	defined	as	the	number	of	true	positive	cases/	number	of	true	positives	and	
false	negatives.	Specificity	is	defined	as	the	number	of	true	negatives/	number	of	true	
negatives	and	false	positives.	Sensitivity	was	88%,	with	a	specificity	of	50%.71
Section 11 – Discussion
11.1 – Background 
Breast cancer remains the most common cause of cancer in women in the UK. In 2006, 
breast cancer accounted for 17% of female deaths from cancer in the UK and was the 
most common cause of death from cancer in women until 1998; since then there have 
been more deaths from lung cancer(106).
Although survival has improved in recent years, novel and effective, non-toxic approaches 
to therapy in patients with metastatic or relapsed breast cancer remain elusive.
A seminal publication in breast cancer research was published in Nature Medicine in 2000 
by Tazebay(75). This suggested the intriguing prospect that the physiological pathways 
whereby iodide is taken up into thyroid cells and incorporated into thyroid hormones 
could	be	exploited	for	therapy	in	breast	cancer.	A	major	step	in	the	process	of	iodide	
uptake is mediated by NIS – the sodium iodide symporter. This protein was determined 
to be the main transporter in iodide uptake into thyroid cells, in the 1990s, and Tazebay 
demonstrated the presence of NIS protein, by IHC using 2 polyclonal antibodies, and one 
monocolonal anti-NIS antibody, in 87% of human breast cancer samples examined. The 
possibility of endogenous expression in breast cancer was exciting, given the interest in 
research	incorporating	a	range	of	different	methods	to	artificially	induce	NIS	expression	
in a variety of cancers. Radioisotope therapy has a long and safe record of utility in thyroid 
cancer, and would be a valuable addition to the armamentarium of therapies available in 
metastatic breast cancer, should endogenous NIS expression in breast cancer translate 
into clinical relevance.
However,  a  further  clinical  study  by  Wapnir  in  2004(79)  showed  that  the  incidence 
of  NIS  positivity  in  breast  cancer  cells  may  not  be  as  high  as  initial  studies  had 
suggested. In Wapnir’s study, of the 23 samples analysed for NIS protein expression 
by immunohistochemistry, eight demonstrated NIS expression (34.8%), and only two of 
these patients demonstrated uptake on scintigraphy (7%).72
Positive	immunostaining	was	defined	as	being	present	if	>20%	of	cells	demonstrated	
brown immunostaining. The presence of plasma membrane staining was noted, but the 
incidence not reported in their paper. In nine of the 23 patients, metastatic tissue was 
available for analysis, in addition to the primary tumour. Of note 87% of the NIS positive 
cases in Wapnir’s study were ER negative. Moon, however, demonstrated radio-isotope 
uptake of Tc99m Pertechnetate in four of 25 breast cancer patients(77). It was also noted 
that these four patients had comparatively higher levels of NIS mRNA as compared with 
those patients whose tumours did not take up radio-isotope.
The above studies suggest that NIS positivity and uptake in breast cancers may not be as 
high as initially thought in the landmark Tazebay study. However, a level of 34.8 % NIS 
expression	compares	well	with	the	level	of	Her2/neu	over-expression	or	amplification	
seen in breast cancer of approximately 20%, a target which is in routine use for therapeutic 
manipulation.
11.2 – Current study
11.2.1 – Immunohistochemistry
Initial review of the available literature regarding immunohistochemical methods used 
to detect the presence of NIS protein in metastatic breast cancer and thyroid cancer, 
suggested the use of the mouse anti-NIS monoclonal antibody Chemicon, MAB3564(107). 
This antibody was initially optimised by using a variety of staining conditions on samples 
of differentiated thyroid cancers. While this antibody was effective when used to stain 
differentiated thyroid samples, a panel of 25 random breast cancers and 20 study patients 
stained poorly, in terms of intensity, and number of cells demonstrating staining.
In view of the relatively poor staining seen with this monoclonal antibody, a literature 
search was performed to identify workers in this area. To this end, contact was made 
with Professor Jhiangs’s group in Ohio, US. They kindly agreed to the loan of their rabbit 
anti-NIS polyclonal antibody. The suggested protocol was as described in section 6.2.8.2. 
It was found, however, that staining was superior using the DAKO Autostainer machine 
with this rabbit anti-NIS polyclonal antibody.73
It has been previously reported that Graves’ disease of the thyroid was the most effective 
positive control (Jhiang, personal communication). This, in fact stained very strongly and 
was used as a positive control and a reference for membrane staining of 3+ in 100% of 
cells (Histoscore 300) (see figure	nine).
If	patient	X	is	included,	15	cases	were	defined	as	truly	immunopositive,	with	the	criteria	
for true positivity being a Histoscore of > 150, or demonstration of membrane staining. 
Seven cases were negative by the above criteria. See table four for immunocytochemistry 
results,	and	figures	11-12 for examples of immunostaining from study patients. 
This represents a prevalence of NIS staining in study patients of 68%. In this study, of the 
14 NIS positive cases where oestrogen receptor results were available,  seven were ER 
negative (50%) and seven were ER positive (50%). 
Interestingly none of the random breast cancer samples had positive IHC assessed by 
the	polyclonal	antibody	(see	table	five).	This	may	have	been	due	to	the	relatively	small	
sample size. 
11.2.2 – Imaging 
Tc99m Pertechnetate uptake was demonstrated in 11 of 24 patients who were scanned 
(46%).
Of those patients who demonstrated uptake of Tc99m Pertechnetate, characteristics were 
as	follows:	on	conventional	imaging,	no	patients	had	bone-only	metastatic	disease,	five	
patients had visceral and bone metastatic disease, one patient had breast and possibly 
nodal disease, one patient had visceral and soft tissue disease, one patient had soft tissue 
disease only, one had visceral, bone and nodal disease, and two patients had nodal only 
disease. Uptake was seen in all known disease in only two patients and this was nodal 
disease in the supraclavicular fossa in one patient (patient 10) and a soft tissue mass near 
sternum in the second (patient 19).
Differential uptake, i.e., uptake in some of a patient’s known metastatic lesions, but not 74
others,	of	Tc99m	Pertechnetate	was	seen	in	the	majority	of	patients	who	demonstrated	
uptake	(nine	patients).	Of	the	five	patients	who	had	known	metastases	in	bone	and	
viscera, three (patients three, six and 20) demonstrated Tc99m Pertechnetate uptake in 
only some of their bone metastases, and not at all in their visceral metastases. Patient 
23 demonstrated uptake in all known bone metastases in her spine, but not in the known 
visceral disease in her small bowel. Patient 16 had positive uptake in her pleural effusion 
only, not in bone or liver metastases. 
The patient (patient 13) with breast and possible axillary nodes, had uptake only in the 
biopsy proven breast cancer, not axillary nodes, but it was unclear if these nodes were 
reactive or contained malignant deposits. Patient 14 had known disease in viscera and 
chest wall, but only demonstrated uptake in the large chest wall lesion, not small lung 
metastases.
Patient 22 had metastases in viscera, bone and nodes. Uptake was seen only in liver and 
lumbar vertebrae, not in nodes, thoracic spine, ribs or pelvis. Patient 24 had metastatic 
disease in two nodal areas, but demonstrated uptake in only one of these. 
Overall, it seems that Tc99m Pertechnetate uptake is best seen in bone disease as opposed 
to visceral disease. Nodal and soft tissue disease is also fairly well visualised. 
Subjectively,	there	did	seem	to	be	some	difference	between	the	appearance	of	the	4-hour	
and the 24-hour scans generally, in that the patients with bony disease (patients three and 
four), seemed to have more prominent uptake in this bony disease seen at 24 hours as 
compared with the 4 hour scan. Background blood pool activity appeared to have reduced 
at 24 hours and therefore there was better contrast of uptake in the spine compared with 
physiological uptake.  At 24 hours, however, there is also increased activity within the 
bowel due to excretion which impedes image interpretation. In contrast, patients where 
nodal, soft tissue or visceral uptake was seen (patients 10, 13, 14, 16, 19 and 24) seemed 
to demonstrate this best at 4 hours (see appendix two). This would support the policy of 
scanning all patients at two separate time points.   75
Attempts were made to block physiological uptake using perchlorate and potassium 
iodate. Perchlorate and potassium iodate did seem to appreciably reduce the physiological 
uptake of Tc99m Pertechnetate by a number of organs, including thyroid and bowel. This 
was a preliminary study, where it was felt that it would be useful to look at a number of 
blocking	methods,	to	find	the	most	useful	agent	and	dose.	Following	this	study,	this	would	
be regarded as being potassium iodate, as there was no great temporal effect as seen with 
perchlorate. Also, physiological blocking was observed. Clearly, only small numbers 
have been scanned with this method, and further studies would be required.  
Other workers have used a low iodine diet in combination with T3 and methimazole to 
suppress thyroidal uptake(79). This was seen to be useful in suppressing thyroidal uptake 
in that dosimetric study. This may be a further useful approach in future work, but in this 
study, it was felt that examining perchlorate at escalating doses and potassium iodate, 
would be more valuable in terms of assessment of physiological blocking.   
11.2.3 – RNA analysis
One	of	the	stated	aims	of	this	project	was	to	extract	RNA	from	paraffin	embedded	tissue,	
and analyse this for NIS expression. A technique was developed for extracting RNA 
reliably from patient’s archival samples (Ambion method). Although GAPDH signal 
could	readily	be	detected,	it	was	not	possible	to	detect	NIS	signal	from	paraffin	embedded	
breast tissue.
It was proven that the RNA quality was good, as GAPDH was consistently detected, and 
analysis	by	Nanodrop	confirmed	quality.	It	was,	however,	possible	to	detect	a	NIS	signal	
from	paraffin	embedded	cells	extracted	from	a	NIS	expressing	cell	line.	This	suggests	that	
it	is	not	the	formalin	fixation	and	paraffin	embedding	process	that	renders	NIS	undetectable	
in these samples. It was also possible to detect NIS positivity in RNA which had been 
extracted	from	paraffin-embedded	Graves	thyroid	tissue,	suggesting	that	this	method	is	
sensitive,	but	not	sufficiently	so	to	detect	NIS	in	paraffin-embedded	breast	tissue,	where	
NIS is likely to be less abundant. It is clear from the literature(108) that RNA can be reliably 
extracted	from	fresh	tissue,	but	extraction	from	paraffin	embedded	tissue	is	significantly	76
more challenging(101)(109). A number of factors have been shown to contribute to poor yield 
of RNA and may have been important in this study. These contributing factors are likely 
to  have included the age of tissue, and therefore the length of time it has been stored. 
The median duration of storage of tissue used in this study was 5.3 years (range one to 19 
years).		The	efficiency	of	amplifying	mRNA	in	paraffin-embedded	blocks	has	been	shown	
to	be	greatly	affected	by	time	spent	in	paraffin(110).
It	has	been	shown	that	abundance	of	quantifiable	RNA	fragments	is	lower	in	fixed	tissue	
compared	with	fresh	tissue,	and	this	effect	is	magnified	at	larger	amplicon	sizes(111). NIS 
primers	and	probe	used	in	the	majority	of	my	study	detected	137	base	pairs	amplicon	size.	
GAPDH primers and probe were designed to detect an amplicon of 118 base pairs.
It	seems	likely	that	storage	time	in	paraffin,	and	processing	may	cause	large	proportions	
of RNA in samples to be degraded. GAPDH, being a housekeeping gene, is likely to be 
present more abundantly than NIS; therefore it is likely that a small amount of GAPDH 
RNA will be detectable long after NIS RNA has completely degraded.
It also appears that different RNA species have different half lives in cells, with several 
factors	 contributing	 to	 RNA	 longevity	 including	 mRNA	 length,	 and	 more	 specific	
determinants such as stability/instability elements in coding regions, for example(112)(113). 
These may be contributory factors in why GAPDH is consistently detected, but NIS is not 
in the breast cancer tissue.  
In	conclusion,	analysis	of	RNA	extracted	from	paraffin	embedded	breast	cancer	tissue	did	
not yield consistently reliable results. It was not reasonable or practical in my study to 
attempt to obtain fresh tissue from patients to allow analysis of RNA. It may be possible 
in the future, however, to obtain fresh tissue at the time of diagnosis of breast cancer, to 
assess for presence or absence of a panel of genes. NIS analysis at this stage may be useful 
for staging imaging with radio-isotope, to assess whether radio-isotope may be a useful 
therapy at time of relapse, or to assess its therapeutic use at an early stage. However, the 
sensitivity	and	specificity	of	the	screening	test	would	have	to	be	vastly	improved,	to	be	77
clinically applicable.  
11.3 – Comparison Between Current Study and Wapnir’s Study
The study by Wapnir et al evaluated 27 patients(79).	This	present	study	assessed	24	subjects,	
and therefore represents the second largest study of radioisotope scanning in patients with 
breast cancer.
The mean age of patients in the Wapnir study was 50.4 years, as compared to 56 years in the 
current study. In the Wapnir study, seven of the eight patients (87.5%) who demonstrated 
NIS positivity on IHC were ER negative. In their paper, they comment that up-regulation 
of NIS in malignant cells may therefore be an oestrogen-independent event, and this is 
also seen in Tazebay’s work(75), where transgenic mice carrying oestrogen-independent 
breast tumours take up iodide. In contrast, in this current study, seven of the 14 (50%) 
patients who were NIS positive by IHC demonstrated ER positivity. In this study, patients 
who  were  on  hormonal  therapy  were  excluded  from  recruitment;  however,  ongoing 
chemohormonal treatments were not interrupted in Wapnir’s study. It is unclear how 
hormonal treatments may affect NIS expression. It seems from Tazebay’s experiments, 
that oestrogen levels can affect NIS expression albeit in a complex fashion(75). The higher 
numbers of patients with NIS positivity on IHC in the current study, who demonstrated 
ER positivity also, may be related to the lack of manipulation of hormonal status by 
therapeutic agents, but the numbers are too small to draw any conclusions.   
The present study showed a greater number of patients with Tc99m Pertechnetate uptake 
than the Wapnir study (46% versus 14%). In Wapnir’s study, only 1 patient demonstrated 
Tc99m Pertechnetate uptake, which was in an axillary metastasis (14% of patients had 
a positive scan therefore). However, in the Wapnir study, only seven patients received 
Tc99m Pertechnetate. These seven patients received a lower administered activity of 
Tc99m Pertechnetate than in the present study, (5-15mCi - equivalent to between 185 
and 555 MBq versus 600 MBq in the present study). Scanning was performed at 15, 
30, 60 and 120 minutes only (as compared with 4 and 24 hours in the present study).   
Therefore, although the number of patients scanned with Tc99m Pertechnetate was small 78
(seven) in the Wapnir study, the percentage of patients showing uptake were not as high 
as in the present study and the reasons may include lower administered activity of Tc99m 
Pertechnetate, and earlier timing of scans. The timescale of scans in the present study 
was agreed in the study protocol to allow detection of differential uptake in metastases 
between early and late images.
After these seven patients had been scanned, Wapnir’s group changed their protocol to 
using the radio-isotope I123 to allow retention studies to be performed. Only one patient 
who was scanned in the latter part of the Wapnir study using I123 had positive uptake out 
of 20 patients scanned (5%). 
In summary, in the present study, 24 patients received 600MBq of Tc99m Pertechnetate and 
were scanned at 4 hours and 24 hours. Eleven, i.e. 46%, demonstrated uptake of Tc99m 
Pertechnetate in a range of bone and other lesions. This would suggest that the scanning   
protocol used in this study was superior to that in Wapnir’s study, and should be explored 
in future studies.
11.4 – Summary
This  data  has  shown  that  the  prevalence  of  patients  with  metastatic  breast  cancer 
expressing	NIS	on	immunohistochemistry	is	relatively	high	(15	of	22	samples:	68%),	
when compared with 1 other published study of similar patients(79). The original Tazebay 
data demonstrated higher NIS expression by IHC, but this was in primary breast cancer 
tissue harvested at the time of IHC. Also, it has been demonstrated that a high proportion 
of NIS IHC positive patients who were scanned (eight of 14 – 57%) demonstrated uptake 
of Tc99m Pertechnetate in breast cancer primary tumour or metastases.
The question this study poses is “does immunohistochemistry as performed here provide 
a useful screening test to select patients who should go on to have Tc99m Pertechnetate 
scanning performed?”
With	a	negative	predictive	value	of	86%,	and	a	sensitivity	of	88%,	the	large	majority	
of patients who would have a negative scan would be correctly detected, and not be 79
subjected	to	further	tests.	The	positive	predictive	value	of	57%,	and	specificity	of	50%	
associated with this screening test would clearly not correctly detect all those patients who 
would	be	likely	to	benefit	from	Tc99m	Pertechnetate	therapy,	but	those	patients	who	were	
destined to have a negative scan would later be excluded from therapy when they had their   
scan performed. This would suggest that it would be prudent to screen out those patients 
who  demonstrate  negative  IHC,  with  a  relatively  straightforward  and  noninvasive 
examination of FFPE breast tissue available from the surgical specimen, and proceed 
to perform radio-isotope imaging, in those who demonstrated positive IHC i.e., that   
IHC	 does	 act	 as	 a	 useful	 screening	 test	 for	 those	 who	 may	 ultimately	 benefit	 from	
radioisotope treatment.    
In this study, six of 12 cases which displayed no uptake by Tc99m Pertechnetate, where 
IHC was available, would have been deemed to have negative immunohistochemistry 
by the above criteria. The other six would have been deemed positive by IHC, but on 
subsequent scanning would not have demonstrated uptake in their metastases and therefore 
would have been considered unsuitable for therapeutic radioisotopes.
The question of why some (six of 14 IHC positive cases – 43%) of samples should 
demonstrate NIS immunoreactivity, but not take up Tc99m Pertechnetate scintigraphically 
is  an  interesting  one.  Of  those  patients  with  positive  immunohistochemistry,  who 
ultimately had negative scans, four of the six did not demonstrate membrane staining, 
perhaps suggesting a lack of functional NIS protein in these samples. It seems that simply 
demonstrating	NIS	positivity	in	the	original	breast	cancer	sample	is	not	sufficient	to	
assume NIS functional activity leading to Tc99m Pertechnetate uptake in known disease 
in every case. 
In the present study, four patients (seven, 10, 15 and 19) were seen to have plasma membrane 
positivity on IHC. However, two of these (10 and 19) demonstrated isotope uptake and 
two did not (seven and 15). These are small numbers to be able to draw conclusions, but 
it may be that the discussed mechanisms that render metastases NIS negative by IHC over 
time are involved. This was also demonstrated in the Wapnir study, where eight cases 80
showed NIS expression, but 6 did not demonstrate uptake (75%). Wapnir’s paper states 
that presence of plasma membrane NIS positivity was noted. However, the number of 
samples demonstrating this was not given in the paper.  
There is recent evidence suggesting that NIS activity in thyroid cells requires not only 
TSH stimulation, but also cell polarisation and spatial organisation of thyrocytes into 
follicles(114). There are also reports that some thyroid cancers overexpress NIS, but this 
does not always translate to increased iodide uptake, whether due to faulty targeting of 
NIS	to	the	plasma	membrane	or	insufficient	retention	of	NIS	in	the	plasma	membrane(115)
(116)(117). It may be of relevance that only I- and not I2 uptake is affected by NIS expression, 
at least in breast cancer cells(82).       
PI3K protein upregulation in breast cancer cells may be important here(83). This protein 
seems	to	interfere	with	NIS	cell	surface	trafficking	leading	to	localization	of	NIS	in	the	
cell rather than at the cell surface, perhaps explaining why NIS positive breast cancer may 
not always take up radioiodide. Many oncogenes that are implicated in the development 
and progression of human breast cancer upregulate PI3K signalling, and there seems to be 
differential effects of PI3K in thyroid and breast cancers. This may be a future potential 
target for manipulation of improved radioisotope uptake in NIS positive breast cancers.    
Disease	progression	has,	by	definition,	occurred	in	all	the	patients	between	the	time	when	
their primary breast cancer was removed and when they were receiving treatment for 
metastatic disease. This may have led to altered expression of NIS function affecting 
scintigraphic  uptake  as  can  be  seen  in  thyroid  cancer(118).  Min  demonstrated  that   
seven  of  11  lymph  node  metastatic  differentiated  thyroid  cancer  tissues  showed 
loss  of  NIS  expression  by  IHC,  despite  showing  expression  in  the  primary  thyroid   
cancer(78). This was also demonstrated in the Wapnir paper, where in two cases in which 
the primary breast cancer tissue and metastatic tissue were analysed together, it was 
demonstrated that the primary showed weak NIS positivity, but the metastases were NIS 
negative. This must be presumed to be the effect of interval treatments, or through the 
effects of disease progression on NIS expression. In the Wapnir study, there were in total 81
six cases showing NIS positivity, but no scintigraphic accumulation. Although primary 
and metastases were not available in every case, the same mechanisms may be assumed 
to be at work.   
In the current study 17 of 24 patients were on some form of therapy at the time of their 
Tc99m Pertechnetate scan, and this may alter NIS expression over time (see table 10). In 
only one case in the present study was the sample harvested contemporaneously – patient 
13,	a	patient	having	neoadjuvant	chemotherapy.	Unfortunately,	her	sample	was	a	core	
biopsy only and not adequate in terms of size for analysis of NIS expression. It was not 
felt	ethical,	generally,	to	subject	patients	to	additional	biopsies	for	the	purpose	of	the	study,	
and therefore original tumour samples were analysed rather than metastatic samples.   
Of note, one patient (patient 14) demonstrated uptake scintigraphically, but the operative 
sample did not stain positively for NIS. This may have been because the sample had 
degenerated, although this case was only stored for two years prior to analysis.
11.5 – Future Work
The	 polyclonal	 antibody	 produced	 reliable	 staining,	 but	 RNA	 analysis	 of	 paraffin	
embedded tissue for expression of NIS was not reliable. The RNA longevity/degradation 
that has been discussed may have been important here. An experiment could be performed 
on	paraffin	fixed	samples	analysed	at	0	hours,	24	hours,	one	week	and	one	month	after	
biopsy to assess copy number of NIS and GAPDH by Taqman analysis. This could be 
correlated with NIS positivity on IHC.  
Whilst uptake was demonstrated in 57% of cases with positive IHC, there is scope to 
improve upon this. Akin to the situation with thyroid cancer and TSH stimulation by 
withdrawal of Thyroxine or use of recombinant TSH, which leads to improved uptake on 
thyroid scans, there may be ways to maximise Tc99m Pertechnetate uptake in breast cancer 
patients. It has been demonstrated in the ER positive breast cancer cell line MCF-7 that 
all-trans Retinoic Acid (ATRA) could stimulate iodide uptake up to 9.4 times baseline 
levels(119). Retinoids are known to be involved in cell differentiation(120), and there is 82
evidence for their effect on thyroid NIS expression. Encouraging results have been seen 
using ATRA in dedifferentiated thyroid cancers(121). It has also been demonstrated that 
dexamethasone potentiates the effects of ATRA(122)(123).   
There is some evidence that ATRA induction of NIS expression may be limited to ER 
positive cells only(119). It was postulated by these authors that ER positivity may lead to 
increased	levels	of	Retinoic	Acid	Receptor	(RAR)	in	the	presence	of	17-β-estradiol (E2), 
which may provide cellular conditions favorable for NIS expression. It is interesting to 
note that in the current study 50 % of patients who expressed NIS by IHC, were also seen 
to have ER positive tumours by IHC. 
A	novel	ERE	(oestrogen	responsive	element)	has	been	identified	in	the	NIS	gene	promoter.	
It has been shown by these authors that ER negative cell lines can be induced to express 
ER, and thereafter demonstrate ATRA induction of NIS expression(124). In summary, future 
experiments could look at improving NIS expression and hence uptake in breast cancer 
patients using agents such as ATRA, or dexamethasone.  
A further step, may be to look at the use of radio- isotopes with more potent cell kill effect 
such as Astatine (211At). This is a radionuclide with many similar biological qualities to 
iodide, which decays by emission of high linear energy transfer alpha particles with short 
tissue	range	(60	μm)	and	greater	cytotoxicity,	compared	to	β-particles	derived	from	the	
decay of 131I. Carlin demonstrated 211At distribution similar to that of 131I in a NIS cell 
line(125), and Brown showed similar distributions in murine xenograft models of thyroid 
carcinoma(126).  However, concerns over normal tissue uptake, particularly in lung and 
spleen, have prevented clinical trials of  211At, therefore minimisation of normal tissue 
uptake	of	astatine	is	now	a	major	priority	in	the	development	this	radionuclide.	Carlin	has	
suggested the development of cultured cell models to allow the study of the molecular 
mechanisms involved in astatine uptake. 
A further recent study has demonstrated acceptable normal tissue effects in prostate cancer 
mouse models treated with astatine, but suggested due to short path length, this therapy 83
may be best reserved for treatment of small tumours or micrometastases only(127). However, 
the short half-life of 211At	at	7.2	hours,	provides	difficulties	in	terms	of	production	for	a	
nuclear medicine department.     
Other investigators have looked at the radioisotope 188ReO4
−
.  For maximal radiobiological 
effect of a radioisotope and thus increased dose to tumour, biological T1/2 should match 
the radiological T1/2 of the isotope administered (in the case of 131I this is eight days). 
188ReO4
−	 (perrhenate), a beta-emitting chemical analogue of technetium, with similar 
characteristics is concentrated in the thyroid and stomach by endogenous NIS(128).  A 
report(129) of the biodistribution of perrhenate (radiological T1/2 = 16.7 hours) in mouse 
mammary tumours expressing NIS, estimated an increase in tumor dose compared with 
125I, due in part to the comparatively shorter radiological T1/2. Perrhenate is an attractive 
radioisotope, as it can be conveniently used on site in nuclear medicine departments, 
due to the long half life of its parent compound (69 days) and it has higher energy beta 
particles than 131I (0.764 MeV), leading to a greater range than 131I. Its gamma photon 
emissions are easier to shield than those of 131I, and produce good quality images.  
Improved  retention  of  radio-isotope  may  be  another  potential  target.  This  has  been 
examined by a number of investigators and one method is coupling NIS gene transfer 
with Thyroid peroxidase (TPO) gene transfer as mentioned in section 4.5. TPO catalyses 
the	organification	of	iodide	i.e., its conversion from inorganic to organic form, allowing 
retention	in	the	thyroid	gland	for	several	days.	Boland	postulated	that	the	organification	
process in which TPO is involved could cause longer radioisotope retention time and 
significantly	higher	radiation	dose	to	be	delivered	to	tumour,	although	this	has	proved	
difficult	to	achieve	in	cervix	cell	lines(90). However, Huang showed that the transfection 
of non-small cell lung cancer (NSCLC) cells with both NIS and TPO genes did lead to 
increased radioiodide uptake and retention, as well as to enhanced tumour cell kill(91). A 
future direction could be to transfect NIS and TPO into breast cancer cell lines.  
As described in section 11.4, PI3K may be a future potential target for manipulation of 
improved radioisotope uptake in NIS positive breast cancers.  84
The next logical step in development of the clinical use of NIS expression in breast cancer 
would be to run a further clinical study, where patients are screened by IHC analysis of 
NIS expression in breast tumour samples, and those with a Histoscore above 150 would 
proceed to a Tc99m Pertechnetate scan, using potassium iodate blocking, in an attempt to 
avoid the temporal effects seen with perchlorate. It may also be worth examining the use 
of 123I as an imaging agent, and investigating administering perchlorate and potassium 
iodate as blocking agents to the same patient at different time points. 
A therapy dose of 131I could be administered to those patients with positive uptake of Tc99m 
Pertechnetate.  Tc99m Pertechnetate is not a suitable therapy agent as it has too short a half 
life and low energy gamma emissions. It would also be interesting to perform a dosimetric 
study of 131I to review whether treatment doses are likely to be achieved in vivo. 
Finally, it would be interesting to examine the uptake seen in primary breast cancers, 
and examine IHC from relatively fresh tissue, to see if yield would be higher. This early 
stage of disease may be a more appropriate clinical scenario for NIS therapy, before NIS 
expression may have been altered due to passage of time and therapeutic interventions. 
Recent data have been presented at ASCO 2008 which suggest early intervention with 
bisphosphonates, may prevent recurrence of breast cancer in patients at high risk of 
relapse following primary surgery(130).  85
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Table One – Nanodrop results
Sample  Nanodrop purity A260/280 Nanodrop concentration (ng/ul) 
1 1.92 53.34
2 1.78 19.44
3 Not done Not done
4 1.99 145.55
5 2.02 88.8
6 2.06 168.4
7 1.98 60.1
8 2.01 321.36
10 2.0 680.8
11 0.8 9.55
12 1.99 468
13 Not done Not done
14 1.93 390.6
15a4- nodal 1.98 31.55
15a7- lymphatics 1.98 201.59
16 1.88 1046
17 1.9  1.9
18 1.96 56.64
19 1.98 444.27
20 1.94 125.24
21 2.06 278.9100
Technique Tissue used Deparaffination Digestion Purification RT-PCR
Quiagen 
Minikit
FFPE thyroid 1 
year old
Xylene and 
100,70,50 and 
20% ethanol. 
Buffer RLT Spin column 2 step 
kit. NIS 
137bp, 
GAP 
432bp 
primers.
ZYMO As above As above Buffer and 
prt K 4 
hours 55°C
Spin column As above
Trizol FFPE thyroid, 
fresh breast, 
thyroid and NIS 
cell pellet
Xylene and 100% 
ethanol. Vaccum 
dessicate dry 5 
mins 
Tris HCL, 
10% SDS 
and prt K 
o/n at 37°C 
in water 
bath 
Trizol, 
chloroform 
and 
isopropanol
1 step 
kit. Used 
PBG 
65 and 
265bp 
primers.  
Purescript As above As above, but air 
dried. 
Prt K and 
glycogen o/n 
at 55°C in 
rotary oven
Prt-DNA 
precipitation 
solution, 
isopropanol 
and RNA 
hydration 
solution.
2 step 
kit. Used 
PBG 
65bp 
primers.
Ambion FFPE breast  Xylene and 100% 
ethanol
Proteinase 
and Buffer 
Filter 
cartridge
2 step 
kit and 
Taqman
Table 2: RNA extraction techniques used101
Group Antibody Tissue 
used 
Dilution Antigen 
retrieval
Peroxidase 
blocking
Ab incu-
bation
Wapnir (76) Rabbit 
polyclonal 
antibody  
against C 
terminus 
peptide of 
human NIS
Human 
breast 
cancer, 
primary 
or meta-
stases. 
1 in 
10,000
10% citrate 
buffer 45 
minutes
3% 
hydrogen 
peroxide/  
methanol 
15 minutes 
pre Antigen 
retrieval
15 mins
Castro 
(103)
Mouse 
monoclonal 
antibody 
against C 
terminus of 
human NIS
Human 
normal 
thyroid 
gland, 
Graves 
disease, 
and differ-
entiated 
thyroid 
cancers 
1 in 1500 10% citrate 
30 minutes
As above 10 
minutes
1 hour
Jhiang 
(personal 
comm-
unication)
Rabbit 
polyclonal 
against 
human NIS
Human 
breast 
1 in 500 
to 1000
Citric acid 
30 minutes 
As above 1 hour
Tazebay 
(75)
Rat polyclonal 
antibody 
against C 
terminus 
of human 
NIS and, rat 
monoclonal 
antibody  
against C 
terminus of 
human NIS
Human 
normal 
breast and 
breast 
cancer 
1 in 750 
to 100 
10% citrate 
buffer  
DAKO 
system
15 
minutes
Spitzweg 
(92) 
Mouse 
monoclonal 
antibody 
against C 
terminus of 
human NIS
Mouse 
prostate 
cancer
1 in 1600 Citrate 30 
mins
Not specified 90 
minutes
Table 3: IHC methods used by other groups102
Patient  Histoscore Intensity 
(0-3)
% Cells 
Staining
Cytoplasmic or 
Membranous 
Staining
Overall 
positive or 
negative 
result
1 200 2+ 100% Cyto only positive
2 100 1+ 100% Cyto only negative
3 160 2+ 80% Cyto only positive
4 160 2+ 80% Cyto only  positive
5 160 2+ 80% Cyto only positive
6 300 3+ 100% Cyto only positive
7 160 2+ 80% Cyto/mem positive
8 80 1+ 80% Cyto only negative
9 Sample not available
10 160 2+ 80% Cyto/ patchy mem 
staining
positive
11 100 1+ 100% Cyto only negative
12 80 1+ 80% Cyto only negative
13 NA – poor sample 
14 20 1+ <20% Cyto only negative
15 a4-
nodal 
tissue
200 2+ 100% Strong mem and 
cyto
positive
15 a7-
lymphatics
300 3+ 100% Strong mem and 
cyto
positive
16 180 2+ 90% Cyto only positive
17-nodal 
tissue
80 1+ 80% Cyto only negative
18 160 2+ 80% Cyto only positive
19 100 1+ 100% Some mem 
staining and 
100% cyto
positive
20 160 2+ 80% Cyto only positive
21 80 1+ 80% Cyto only negative
22 160 2+ 80% Cyto only positive
23 300 3+ 100% Cyto only positive
24 Sample not available
X (not 
scanned)
160 2+ 80% Cyto only positive
Table 4: Immunohistochemistry results103
Patient 
number
Intensity 
staining 
(0-3)
% Cells 
staining
Histoscore Cytoplasmic 
or membrane 
staining
1 1+  40 40 Cytoplasmic
2 2+ 60 120 Cytoplasmic
3 1+ 10 10 Cytoplasmic
4 1+ 50 50 Cytoplasmic
5 1+ 80 80 Cytoplasmic
6 0 0 0 Cytoplasmic
7 1+ 70 70 Cytoplasmic
8 2+ 10 20 Cytoplasmic
9 0 0 0 Cytoplasmic
10 1+ 30 30 Cytoplasmic
11 0 0 0 Cytoplasmic
 
Table 5: Random breast samples immunostaining results 104
Patient 
number
Site of 
disease on 
conventional 
imaging
Visceral/
bone /
soft 
tissue
Type of 
imaging/
assessment
Proximity 
to NIS 
scan 
Differential 
uptake on 
pertechnetate 
scan?
1 Liver/lung/ bone/
axillary and 
mediastinal 
nodes
Visceral/
bone/
nodal
CT 1 month No Uptake
2 Liver/bone/ovary  Visceral/
bone
CT 2 months No Uptake
3 Liver/lung/ bone Visceral/
bone
Bone scan, USS 
liver, MRI spine, 
cxr
3-4 
months
Yes
4 Lung/Bone/
brachial plexus  
Visceral/
bone/
nodal 
CT 1 week No Uptake
5  Lung/chest wall  Visceral/
soft tissue
CT and clinical 
assessment (CA)
CT  6 
months, 
regular CA 
No Uptake
6 Lung/bone Visceral/
bone
CT and bone 
scan
7 months Yes
7 Lung/chest wall Visceral/
soft tissue
CT and CA 4 months, 
regular CA 
No Uptake
8 Lung/ 
mediastinal 
nodes
Visceral/
nodal
CT 1 month No Uptake
9 Liver/bone Visceral/
bone
CT 1 month No Uptake
10 Supraclavicular 
nodes
Nodal CT 2 months No 
11 Bone Bone CT 1 month No Uptake
12 Bone Bone CT and bone 
scan
1 month No Uptake
13 Primary breast 
lesion/ axillary 
nodes 
Breast 
and local 
nodes
CT and CA 2 months, 
regular CA
Yes 
14 Lung/chest wall Visceral/
soft tissue
CT 2 weeks Yes
15 Pleural effusion, 
sphenoid and 
pelvic masses 
mediastinal and 
neck nodes. 
Visceral/
nodal
CT 1 month No Uptake
16 Liver/ lung/bone Visceral/
bone
CT 1 month Yes
Table 6: details of sites of disease on conventional imaging
Continued on next page105
17 Neck and axillary 
nodes
Nodal CT 2 weeks No uptake
18 Liver/bone/para-
aortic nodes/ 
Visceral/
bone /
nodal
CT and bone 
scan
3-5 
months
No Uptake
19 Chest wall Soft tissue CT 3 months No
20 Liver/ lung/bone Visceral/
bone
CT 3 months Yes
21 Liver/ lung/
bone/axillary 
and mediastinal 
nodes
Visceral/
bone/
nodal
CT 1 month No Uptake
22 Liver/ lung/bone/
neck and axillary 
nodes
Visceral/
bone/
nodal
MRI spine, CT 
and bone scan
3 months Yes
23 Small bowel/
bone
Visceral/
bone
CT and MRI  1-7 
months
Yes
24 Supraclavicular/
axillary nodes 
Nodal CT 3 months Yes
Patient 
number
Site of 
disease on 
conventional 
imaging
Visceral/
bone /
soft 
tissue
Type of 
imaging/
assessment
Proximity 
to NIS 
scan 
Differential 
uptake on 
pertechnetate 
scan?
Table Six continued106
Pt number  GAP ct 
mean 
GAP qty 
mean
NIS ct mean NIS qty mean
1 33.547439 2.81E+05 0 0
2 37.995 1.22E+04 0 0
3 33.40664 144995.92 0 0
4 32.9165 251093 0 0
5 30.883781 641624.1 0 0
6 27.9985 8927596 0 0
7 32.499626 196727.25 0 0
8 30.229 1.40E+06 0 0
10 26.249401 1.36E+07 0 0
11 30.117 2.06E+06 0 0
12 24.603 4.67E+07 0 0
13 28.833942 2695088.2 0 0
14 31.737778 326226.8 0 0
15(nodal)  35.81555 307206.3  0 0
15(lymphatics) 32.168304 146451.14 0 0
16 37.988487  4714.8643  0  0
17 32.111298  252121.31 0 0
18 30.74 1.37E+06 0 0
19 39.719 7.17E+03 0 0
20 38.582405 3130.5415 0 0
21 26.88 1.12E+07 0 0
Positivecontrol 1 
(Graves)
35.50981 26319.035 36.359074 81.607025
Positivecontrol 2 
(NIS pellet)
24.92593 3.33E+07 33.474136 543.1411
Note: patient 9 ommitted.
Table 7: Taqman results107
Patient number Method of 
physiological blocking 
Uptake evident
1 None Minimal thyroid uptake
2 None Thyroid uptake
3 None Thyroid uptake
4 None Thyroid uptake
5 None Thyroid uptake
6 None Thyroid uptake
7 None Thyroid uptake
8 None Thyroid uptake
9 100mg perchlorate Thyroid blocking
10 100mg perchlorate Thyroid blocking
11 200mg perchlorate Thyroid blocking
12 200mg perchlorate Thyroid blocking at 4 hours
13 200mg perchlorate Thyroid blocking
14 300mg perchlorate Thyroid blocking at 4 hours
15 300mg perchlorate Thyroid blocking 
16 300mg perchlorate Thyroid blocking at 4 hours
17 300mg perchlorate Thyroid blocking
18 None Thyroid uptake
19 Potassium iodate Thyroid blocking
20 Potassium iodate Thyroid uptake
21 Potassium iodate Minimal thyroid uptake
22 Potassium iodate Thyroid blocking
23 300mg perchlorate Thyroid blocking
24 Potassium iodate Thyroid uptake
Table 8: Effects of blocking agents108
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Table 9: Pathological status and uptake 
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Table 9 continued110
Table 10: Type of current therapy 
Therapy type Number of patients
Chemotherapy 8
Bisphosphonate 7
Both  2
Nil 7111
Fig 1      NIS Structure
Fig	2						Iodide	transport	and	organification	in	the	
thyroid gland                                                                                                 
Fig	3						Marsden	hospital	flowchart	for	management	
of differentiated thyroid cancer
Fig 4      Inclusion criteria
Fig 5      Exclusion criteria
Fig 6      Ductal breast carcinoma
Fig 7      Thyroid follicular carcinoma
Fig 8      Graves thyroid
Fig 9      Graves control x 40 
Fig 10    Thyroid cancer control x 20 
Fig 11    Example of staining of breast cancer x 20
Fig	12				Example	of	no	significant	staining	of	breast	
cancer x 20
Fig 13    RNA extraction from cell lines, RT-PCR    
Fig 14    Results-RNA extraction -FFPE
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Appendix One
Taqman graphs
Section 15 – Appendices
Amplification plot of NIS standards with 5µM probe and 10µm primer 
concentration, 40 PCR cycles 14/8/6
Slide 1127
Standard curve plot of NIS standards with 5µM probe and 10µm primer 
concentration, 40 PCR cycles 14/8/6
Slide 2
Amplification plot of NIS standards with 20µM probe and 10µm primer 
concentration, 40 PCR cycles 14/8/6
Slide 3128
Standard curve plot of NIS standards with 20µM probe and 10µm 
primer concentration, 40 PCR cycles 14/8/6
Slide 4
Amplification plot of NIS samples and standards 23/8/6
Slide 5 129
Standard curve plot of NIS standards 23/8/6
Slide 6
Amplification plot of GAPDH samples and standards 23/8/6
Slide 7130
Standard curve plot of GAPDH standards 23/8/6
Slide 8131
Figure  1: Uptake in spine, shoulders and pelvis
Appendix Two
Pertechetate images132
Figure 2: Uptake in Left femoral head and mediastinum
Figure 3 : typical 4 hours scan - salivary gland, thyroid gland, and stomach uptake.133
Figure 4: typical 24 hours scan – bowel uptake 
Figure 5 : example of software masking134
Figure 6: Uptake in Left supraclavicular fossa mass  
Figure 7: Uptake in Right breast 135
Figure 8: Uptake in Left pectoral area  
Figure 9: uptake in left pleural effusion136
Figure 10: Uptake in vertebral column
Figure 11 : 4 Hours and 24 hours - 300mg perchlorate137
Figure 12: Uptake medial to Right breast
Figure 13 : Uptake in sternum 138
Figure 14: Uptake in liver and lower lumbar vertebrae
Figure 15: Uptake in Right sided neck nodes139
Figure 16: 4 hours and 24 hours –potassium iodate140
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